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Nature holds innumerable and often unexplored sources of chemical structures 
that have great potential for pharmacological applications. This project investigated 
plant-derived compounds for their potential use as new tuberculosis (TB) drugs. The 
challenges of TB drug development are attributed to the complexity of the disease: 
Mycobacterium tuberculosis (Mtb), the causal agent of TB, can reside in human tissues 
for decades without replicating, but with the potential of resuming growth and developing 
into active TB. Currently, there are no antibiotics that specifically target non-replicating 
Mtb. This project uses ethno-botanical knowledge to navigate the chemical diversity 
found in South African medicinal plants and to identify plant derived compounds with 
inhibitory activity against Mtb. While no plant extracts have previously been tested 
against non-replicating Mtb, our data demonstrates that compounds isolated from 
Warburgia salutaris (Canellaceae) are effective in killing both replicating and non-
replicating Mtb. Furthermore, the compound class drimane sesquiterpenes, characteristic 
of the Canellaceae family, was confirmed as being responsible for the demonstrated 
biological activity. Microarray studies were also completed to gain insight into the 
mechanism of action of drimane sesquiterpenes compounds in Mycobacteria. The data 
suggests that drimane compounds increase the expression of those genes involved in the 
general stress response of the bacteria. Additionally, some of the microarray data 
suggests that these compounds may be targeting the cell wall.       
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CHAPTER 1 
Introduction 
 
1.1. Overview 
 
Tuberculosis (TB) is the leading cause of death worldwide from a single human 
pathogen, Mycobacterium tuberculosis (Mtb). Mtb is transmitted when an infected individual 
generates aerosol droplets, often through coughing or sneezing, which are inhaled by new hosts 
(Dye et al., 2005). The pathology of the disease is complex and not all those who are infected 
will develop the disease. It is estimated that one-third of the world's population, 2.2 billion 
people, are currently infected with the bacterium Mtb (Russell, Barry and Flynn, 2010a). Each 
year, approximately 9 million people develop the disease TB and nearly 2 million people die 
(Rivers and Mancera, 2008). While there are treatments available, these statistics illustrate the 
urgent need to develop more effective treatment options that are capable of eradicating the 
disease (Field et al., 2012). 
   Nature is a source of innumerable, complex and highly varied chemical structures. In the 
past, natural products have been successfully developed into pharmaceutical drugs, especially in 
the treatment of infectious diseases (Pan et al., 2010). This dissertation research project will use 
ethnobotanical knowledge, the study of the traditional uses of plants, to navigate the chemical 
diversity found in nature to identify individual compounds or classes of compounds with anti-
Mtb properties. This project will further focus on South Africa, which is known for its plant 
diversity and for its population’s uses of these plants in the treatment of disease. While several 
places fit these parameters, the country of South Africa is particularly suited for such this inquiry 
due to its high rates of TB infection (Dye, 2005). 
The principal objective of this project is to use the unique knowledge of medicinal plants 
in South Africa to yield novel perspectives on the types of chemical compounds that should be 
considered further in the development of anti-TB therapies. This project will first address the 
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question: are there South African medicinal plants that are effective against replicating or non-
replicating Mycobacterium? Secondly, this project will identify the specific compound(s) or 
classes of compounds responsible for the biological activity. Finally, this project will gain insight 
into the cellular targets of the active compounds. The results of this project will contribute to 
treatment of one the oldest and most difficult to treat epidemics. 
 
1.2. Epidemiology 
 
Mtb is an ancient human pathogen that has existed since the beginning of human history 
(Harries and Dye, 2006). There is genetic evidence that the bacterium has coevolved with 
humans since the time of early hominids between 2.6 and 2.8 million years ago (Gutierrez et al. 
2005). Evidence of Mtb has been found in Egyptian mummies and descriptions of TB are found 
in ancient texts, such as “Of the Epidemics” by Hippocrates in 400 B.C. (Harries and Dye 2006; 
Mathema et al., 2006). Documentation of TB continued throughout history; however, the worst 
mortality rate was throughout the Industrial Revolution. During this time TB was responsible for 
one in four deaths in Europe (Lonnroth et al., 2009). TB was even referred to by writer John 
Bunyan as “the captain of all these men of death” (Bunyan, 1680).  
Even before the first drugs were introduced, TB incidence began to decline throughout 
the early 20th century due to economic growth and the resulting improvements in nutrition and 
living conditions (Lonnroth et al., 2009 ). The introduction of the first TB therapies, beginning in 
the 1940’s, led to a dramatic decline in TB morbidity and mortality (Grange et al. 2009). 
Industrialized countries were able to control the disease with large-scale screenings to identify 
new TB cases and effective treatment. By the 1980’s developed countries considered TB a 
conquered disease (Raviglione and Pio, 2002).  
The success of TB control in Western nations was not shared by less developed countries. 
The strategies of mass testing and specialized case management did not work in resource poor 
countries that lacked the health care infrastructure necessary to provide services to the their 
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entire population (Grange et al., 2009). Furthermore, TB drugs were not affordable to the most 
affected nations. This public health failure eventually converged with the HIV crisis and led to 
the current TB epidemic (Fatkenheuer et al. 1999). In 1993, the World Health Organization 
(WHO) officially declared TB a global health emergency (Zaman, 2010). Today, TB is the 
leading cause of death worldwide. The WHO reports that in 2009 there were 9.4 million incident 
cases of TB and 1.7 million deaths due to the disease (Zaman, 2010). TB continues to 
disproportionately affect resource-poor countries; South-east Asia, Africa and regions of the 
Western Pacific make up 35%, 30% and 20% of TB cases respectively (Dye et al., 2010). 
 
1.3. Pathology 
 
1.3.1 Disease Progression 
Mtb is transmitted from person to person by inhalation of small droplets containing the 
bacterium (Harries and Dye, 2006). However, the presence of the pathogen does not necessarily 
lead to the development of the disease; two other outcomes are possible. A person can develop a 
non-symptomatic, non-contagious form of the disease termed latent TB infection (LTBI). The 
third outcome represents rare and largely uncharacterized cases in which the bacterium is 
completely destroyed by the host's innate responses. The path that the infection takes depends on 
several dynamic interactions between the host and pathogen. The narrative is not simple or 
perfectly linear; the interactions of several types of immune cells must be considered over 
different time scales (Young, Stark and Kirschner, 2008). 
After initial exposure, the bacteria that reach the alveoli (the terminal air spaces of the 
lung) are phagocytized by macrophage and dendritic cells of the host immune system (Young et 
al., 2008). Dendritic cells are then used to signal T-cells, a type of lymphocyte, anywhere within 
5 days to a few weeks post-infection, (Banchereau and Steinman, 1998; Cooper, 2009). T-cells 
are central in cell-mediated immunity and are responsible for stimulating inflammation and the 
activation of the macrophages (Stewart, Robertson and Young, 2003). T-cells migrate to the site 
! 4 
of the infection and surround infected macrophages, forming a granuloma or tubercule (Cooper, 
2009). The structure of the granuloma serves to segregate the infection from the rest of the lung 
and provide a localized environment for the immune cells to act against the infection (Russell et 
al., 2010a).  
In approximately 5-10 % of people infected with Mtb, the immune system of the host is 
not able to control the infection (Harries and Dye, 2006). When granulomas are not adequately 
formed, there is no encapsulation of the infection. The bacteria actively replicate and enlarging 
areas of necrosis of the lung tissue develop (Jagirdar and Zagzag, 1996). Over the course of one 
year, disease symptoms develop, including coughing blood, sputum containing viable bacteria, 
chest pains, fever and fatigue (Boshoff and Barry, 2005). TB is primarily a pulmonary disease; 
however, the bacteria can also spread to other organs (Flynn and Chan, 2001). The presence of 
these symptoms and actively replicating Mtb are what characterize the disease TB, sometimes 
referred to as active TB (Boshoff and Barry, 2005). Infection with HIV, various medical 
treatments, aging, and alcohol or drug abuse can negatively affect the immune response and 
increase an individual’s chance at developing active TB (Flynn and Chan, 2001; Wayne and 
Sohaskey, 2001).  
The most common result of Mtb infection, representing almost ninety-five percent of 
cases, is called a latent tuberculosis infection (LTBI). LTBI describes an individual that has been 
exposed to Mtb, the infection has been established and an immune response develops to control 
but not eliminate the pathogen (Parrish, Dick and Bishai, 1998). LBTI is effectively a stalemate 
between the host and the bacteria. The expression LTBI is widely used, although the term 
dormancy and non-replicating persistent bacteria are also used to describe the bacteria present in 
a person who has an Mtb infection but has no clinical evidence of the disease tuberculosis 
(Wayne and Sohaskey, 2001). 
The immune response of the host to the pathogen is crucial in controlling the infection, 
preventing a latent Mtb infection from developing into active TB. In most cases, this response is 
sufficient to forestall active disease for a lifetime, but because the bacteria are not eradicated, the 
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infection is chronic (Flynn and Chan, 2001; Wayne and Sohaskey, 2001). Viable bacilli have 
been isolated from granulomas in the lungs of persons with clinically inactive tuberculosis, and 
even from cadavers, indicating that Mtb can persist in humans for many decades (Wayne and 
Sohaskey, 2001). Non-replicating bacteria can reactivate years later if the host immune response 
fails (Wayne and Sohaskey 2001; Pieters, 2008). 
 
1.3.2 Understanding the Challenges of Latent Tuberculosis Infections (LTBI) 
The understanding of how the immune system is able to control, but not eradicate Mtb, is 
nascent and far from complete. In response to immune activation, Mtb enters a non-replicating 
state characterized by growth arrest and altered metabolic activity (Flynn and Chan, 2001). 
Investigations have revealed many of the conditions that induce latency including, but not 
limited to: low pH, reduced carbon availability, hypoxia, and the presence of reactive nitrogen 
intermediates (RNI) (Wayne and Sohaskey, 2001). Not all of these conditions pertain to all the 
Mtb present in the host due to heterogeneity between different granulomas and even 
heterogeneity within the same granuloma (Russell et al., 2010b). The evidence for each of these 
conditions is described below.  
 
• Low pH- In the host, Mtb resides primarily in macrophages, more specifically in the 
macrophage’s phagosome, the vacuole where all ingested materials initially reside.  In the 
phagosome of an activated macrophage, the pH ranges from a pH of 6.2 to 4.5 depending on the 
activation state but a pH below 5.5 is associated with cessation of growth of pathogens in vitro 
(Vandal, Nathan and Ehrt, 2009). Further evidence that Mtb is exposed to an acidic environment 
is that pyrazidamide, an antibiotic that kills Mtb in vitro only under acidic pHs, is effective in 
vivo (Vandal et al., 2009). Also, the expression of acid responsive Mtb genes is increased during 
the infection of macrophages (Rohde, Abramovitch and Russell, 2007). 
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• Reactive nitrogen- Mtb-infected macrophages in humans contain the inducible enzyme 
nitric oxide synthase, which produces nitric oxide (NO), a lipid- and water-soluble radical gas 
(MacMicking, Xie and Nathan, 1997).  NO reacts in water with oxygen and yields other radicals, 
including higher oxides, and unstable peroxides. The production of these reactive radicals by 
activated macrophages is considered to be a major anti-microbial response of the host defense 
(Flynn and Chan, 2001). MacMicking et al. (1997) describe the contribution of nitric oxide and 
its derivatives to the functions of the activated macrophage as including: 1) the formation of 
nucleophilic adducts that deaminate nucleosides and cause mutation and 2) the ability to form 
species that oxidize thiol groups, lipids, DNA, and nitrated tyrosines. Other studies demonstrate 
that the products of RNI exert a bacteriostatic effect at low concentrations and a bactericidal 
effect at high concentrations (Firmani and Riley, 2002). 
 
• Hypoxia- It is widely accepted that Mtb in macrophages exist in a low oxygen 
environment based on the relative absence of blood vessels in TB lesions and the poor oxygen 
permeability of necrotic tissues (Wayne and Sohaskey, 2001). Furthermore, in vitro models 
involving controlled reduction of oxygen have shown that Mtb establishes a non-replicating 
state. The bacteria can begin replicating again when conditions become more favorable (Russell 
et al., 2010b). Mtb grown under hypoxic conditions was also found to be less susceptible to 
commonly used antibiotics such as isoniazid, rifampin and ethambutol.  
 
• Carbon source - The sequestration of the bacteria primarily in macrophages limits the 
bacteria’s access to sources of carbon. In turn, Mtb switches to the utilization of lipids and fatty 
acids as alternate carbon sources (McKinney et al., 2000). The full significance of these 
alterations in lipid metabolism is not known; however, there are several observations have been 
made regarding the use of lipids as a carbon source within the host. It is known that Mtb uses the 
glyoxylate cycle to retain carbon when growing on fatty acids as the limiting carbon source. The 
unique enzymes of this route are isocitrate lyase (ICL) and malate synthase (MS). ICL cleaves 
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isocitrate to glyoxylate and succinate, and MS converts glyoxylate and acetyl-CoA to malate. 
The end products can be used for gluconeogenesis and other biosynthetic processes (Dunn, 
Ramirez-Trujillo and Hernandez-Lucas, 2009). It is believed that tubercle bacilli catabolize a 
wide range of fatty acids, since they possess a large number of genes involved in this metabolism 
(Cole et al., 1998). Additionally, bacteria defective in different genes important for lipid 
metabolism, and therefore unable to make this metabolic shift, are shown to be avirulent (Russell 
et al., 2010b) 
 
The conditions that Mtb experience in vivo are important because it is within the context 
of these different environments that TB drugs ideally need to function (Russell et al., 2010b). 
During LTBI, most Mtb are non-replicating and during active TB the some bacteria are 
replicating and some are non-replicating (Nathan et al., 2008; Boshoff and Barry, 2005). 
Conventional bioassays used in developing antibiotics, including those used to produce the 
currently used TB drugs, assay bacteria under growth sustaining conditions and assay for 
inhibition of that growth (Walsh, 2003; Nathan, 2004). Drugs created using these parameters are 
not as effective on non-replicating cultures (Stewart et al., 2003). 
 
1.4. Tuberculosis Treatment  
 
1.4.1 Current Treatment Options 
The current TB treatment regimens as described by the WHO and the Center for Disease 
Control involve a combination of three or four antibiotics taken daily for two months during an 
initial intensive treatment phase, followed by two drugs taken for an additional 4-7 months in the 
continuation or sterilizing phase (Blumberg et al., 2003; Duncan, 2004). This 6-9 month 
regiment is called ‘short-course therapy’ in comparison with the original regiments of the 1950’s 
that took 12-18 months (Blumberg et al., 2003). However current treatments are still considered 
lengthy, cumbersome, and must be completed in order to be successful in eradicating LTBI. The 
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four antibiotics prescribed for the initial treatment of TB, named first-line drugs, are rifampicin 
(RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol (ETH) (Table 1.1). RIF and INH 
are effective with low dose requirements, easily administered orally and are always included in 
the initial 2-month intensive treatment phase (Blumberg et al., 2003). 
 
• The rifamycins are a class of broad-spectrum antibiotics isolated from the bacterium 
Amycolatopsis mediterranei (formerly Streptomyces mediterranei) in 1959 and introduced into 
therapeutic use in 1968 (Sensi, 1983). This compound class, which includes the drug rifampicin, 
specifically inhibits bacterial RNA polymerase, the enzyme responsible for prokaryotic DNA 
transcription, by forming a stable drug-enzyme complex (Campbell et al., 2001). DNA-
dependent RNA polymerase is an enzyme with an α2, β, β‘, σ subunit structure. The binding site 
for rifampicin has been located at the β subunit encoded by the bacterial rpoB gene (Floss and 
Yu, 2005). Bacterial resistance to RIF is caused by mutations leading to a change in the structure 
of the β subunit of RNA polymerase. There are over 35 amino acid substitutions that can lead to 
RIF-resistance (Shin et al., 2005). 
• Vital Chorine, a French doctor, observed that nicotinamide, a water-soluble vitamin in 
the vitamin B group inhibited Mtb (Fox, 1952). This led to the development of structural 
analogues of nicotinamide including INH. INH is a prodrug, metabolized by the endogenous 
mycobacterial enzyme catalase-peroxidase via peroxidation to produce a range of carbon-, 
oxygen- and nitrogen-centered free radical species (Mdluli et al., 1996). The free radicals of INH 
form adducts with both NAD+ and NADP+ and the resulting products are inhibitors of a long-
chain enoyl-acyl carrier protein reductase, InhA (Rozwarski et al., 1998). InhA is involved in the 
synthesis of mycolic acids, the unique and important component of the mycobacterial cell wall 
(He, Alian and Ortiz de Montellano, 2007).   
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Table 1.1. First-Line Tuberculosis Drugs 
 
  
Rifampicin 
 
Isoniazid 
 
Pyrazinamide 
 
Ethambutol 
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• Pyrazinamide (PZA), like INH, is an analogue of nicotinamide. Originally, PZA showed 
negligible activity against Mtb in laboratory cultures, but was found to be highly effective 
against mice infected with TB  (McKenzie et al., 1948). It was later found that PZA has the 
ability to kill non-replicating Mtb that resides in acidic environments (Zhang et al., 2003). It has 
taken sixty years since the discovery of PZA for major progress to be made in determining the 
mode of action of the drug. It was known that PZA is a prodrug hydrolyzed intracellularly to 
pyrazinoic acid. Recently, Shi et al. (2011) determined that POA ultimately inhibits trans-
translation, the process that removes stalled translational complexes, recycling functional 
ribosomes for subsequent use (Keiler, 2008).  It is believed that the ability of PZA to inhibit the 
trans-translation process interferes with survival of Mtb under stress conditions (Shi et al., 2011). 
The introduction of PZA into clinical use played a major role in shortening the duration of TB 
therapy. 
 
• Ethanbutol (EMB) is a first-line drug, however it makes a modest contribution to the 
fight against TB compared to the other first-line drugs. It is primarily used to treat people who 
may have multi-drug resistant Mtb, until their exact bacterial strain has been identified (Jonsson 
et al., 2011). Even as recently as the comprehensive review by Karakousis (2009), the 
mechanism of action of EMB was not completely understood. It is believed that EMB functions 
primarily through the inhibition of arabinogalactan biosynthesis, a structural component of the 
mycobacterial cell wall (Takayama and Kilburn 1989; Mikusova et al. 1995).  
 
To increase the likelihood of proper and complete treatment of TB, the WHO in 1995 
initiated ‘direct observation of treatment, short-course’ (DOTs) where trained personnel 
supervise the dispensation of medication to help increase patient compliance with treatment 
programs (Glaziou et al., 2011). The DOTs program has improved treatment outcomes, but alone 
it cannot create the progress needed to control the disease. The lack of completion of the 
treatment protocols has contributed heavily to the development of resistant strains. This is 
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because resistant strains that develop spontaneously then become established in the bacterial 
population (Goldman, Plumley and Laughon, 2007).  
There are Mtb strains that are resistant to both INH and RIF, called multi-drug resistant 
TB (MDR-TB). In these cases, there are six classes of drugs that can be used as second option, 
called second-line drugs. The treatment of MDR-TB can require antibiotics to be administered 
for up to two years.  MDR-TB is prevalent in countries of the former Soviet Union, South Africa, 
and China and is currently responsible for an estimated 490,000 incident cases of TB and 
110,000 deaths worldwide each year (Banerjee, 2008). In 2006, the term extensively drug 
resistant TB (XDR-TB) was used to describe bacteria classified as MDR-TB that are also 
resistant to three or more of the second-line drugs (Goldman et al., 2007).  
 
1.4.2 New Treatment Options 
No new TB drugs have entered into clinical use in 40 years and structural modifications 
to first-line drugs have not allowed scientists to stay ahead of resistance (Mills, 2006). New 
drugs are needed to shorten the treatment of active disease by addressing the challenge of LTBI 
as well as addressing resistance to improve treatment of MDR-TB and XDR-TB with new modes 
of action (Lange et al., 2007). There are new drugs on the horizon at various stages of clinical 
trials (Glickman et al., 2006). For example, fluoroquinolones are antibiotics used in the treatment 
of several diseases because it has the ability to inhibit DNA gyrase, an essential bacterial enzyme 
that maintains super-helical twists in DNA (Wolfson and Hooper, 1985). This compound class is 
being investigated for its potential in TB therapy. There are other compounds, including 
diarylquinoline and nitramidazoles that represent compound classes with new mechanisms of 
action. These two drugs are being tested in clinical trials and are briefly discussed below. 
However, the mechanisms of action and targets of the other potential new drug classes, such as 
diamine and pyrrole, have not been fully established. Despite these new possibilities, the need 
for new antibiotics will continue as inevitable mutations will eventually allow Mtb to overcome 
each new agent synthesized. 
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• Diarylquinolines, particularly TMC207 (formerly R207910), is a compound class that 
offers a new mechanism of action by specifically targeting the proton pump of mycobacterial 
ATP synthase (Spigelman, 2007). In vitro, TMC207 potently inhibits drug-sensitive and drug-
resistant Mtb isolates and is also bactericidal against non-replicating tubercule bacilli.  
 
• Nitromidazoles do not represent a new drug class, however, they represent a new 
mechanism of action in Mtb. Within this compound class PA 824 and OPC67683 are in clinical 
development (Spigelman, 2007). The nitroimidazole class is derived from a natural product 
called azomycin (2-nitroimidazole), isolated from a streptomycete in the 1950s. The mechanism 
of action of this class is not well understood, however it is believed to acts as a prodrug requiring 
reductive activation of the aromatic nitro group to exert its antibacterial effect (Spigelman, 
2007). 
 
1.5. Natural Products, a Source of New Pharmaceuticals: 
 
1.5.1 Past History of Natural Products in Drug Development  
The innovative chemical structures found in nature can be used as a resource in the 
development of novel antibiotics, including those compounds with anti-mycobacterial properties. 
Drugs of natural origin are defined as compounds: 1) in their original, natural form; 2) derived 
semi-synthetically from natural products; or 3) synthetic products based on natural product 
models (Cragg, Newman and Snader, 1997). While this discussion focuses on plant-derived 
compounds, natural products can be isolated from a variety of sources, including bacteria, fungi, 
plants and animals. Plants have been successfully used in the treatment of disease throughout 
history. Indeed, written evidence of plants being used as analgesics dates back 2300 years when 
Theophrastus wrote about ‘the juice of poppy’, referring to opium poppy, Papaver somniferum 
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(Newman, Cragg and Snader, 2000). The isolation of morphine from opium was the first 
reported isolation of a natural product for medicinal purposes (Huxtable and Schwarz, 2001). 
Natural products have been essential to the development of medicines. The WHO 
compiled a list of what it considers to be essential medicines, approximately 300 distinct drugs 
considered to be essential for a basic healthcare system (Reidenberg, 2010). This list includes 
nearly 210 small molecules and 139 are classified as natural products, 44 are unmodified natural 
products, 25 are semi-synthetic derivatives of natural products and over 70 are synthetic drugs 
based on natural products. Notable examples of the past success of natural products include 
aspirin derived from the willow tree, morphine from opium poppy and digitalis, a heart medicine 
extracted from the Digitalis genus (Mahdi, Mahdi and Bowen, 2006; Hauptman and Kelly, 
1999). In treatment for cancer and infectious diseases, 79% and 75% of these drugs, respectively, 
are of natural origin (Newman, Cragg and Snader, 2003; Newman and Cragg, 2012). 
 
1.5.2 Where Does The Chemical Diversity In Nature Come From? 
 The chemical diversity found in plants comes from secondary metabolites, low molecular 
weight, organic compounds that are not involved in nutrition or essential metabolic processes 
(Maplestone, Stone and Williams, 1992). Over one hundred thousand compounds have been 
identified and extracted from 400,000 flowering plant species, and this represents a small 
fraction of the total universe of compounds that are thought to exist (Goossens et al., 2003). 
There were several theories proposed to explain why secondary metabolites evolved in plants. 
The most widely accepted view is that secondary metabolites arose stochastically, via enzymes 
with broad specificity and chemical reactions that yield multiple products (Firn and Jones, 2003). 
The end result is the production of some compounds that are useful and others with no apparent 
function. This hypothesis is based on the observation that biological activity appears to be a rare 
property for any secondary product to have. However, some compounds do have adaptive 
significance including floral scent volatiles, pigments used to attract insect pollinators, and toxic 
chemicals to protect the plant from pathogens and herbivores (Stamp, 2003). It can be concluded 
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that evolution has favored those organisms that can generate and retain chemical diversity at low 
cost. Those organisms that survived are those that can produce a compound or compounds, 
amongst the many, that meet the challenges of their environment. Different ecological 
environments pose different challenges, and the secondary metabolites are likely to vary 
extensively from species to species and in different ecological environments (Firn and Jones, 
2000). 
 
1.5.3 How Can Researchers Generate Chemical Diversity? 
Scientists trying to identify a chemical structure with a desired biological activity often 
follow the example of nature and attempt to assemble large numbers of compounds with a range 
of structural diversity. One method of doing this is to sample the chemical diversity found in 
nature through the collection of plant extracts and subsequent isolation of compounds with 
demonstrable properties. The establishment of chemical libraries has been successful in 
identifying natural products effective in the development of drug treatments. For example, the 
National Cancer Institute (NCI) developed a large chemical library of natural products and 
natural product derivatives screening program with the goal of identifying new anti-cancer 
compounds (Cragg et al., 1993). From 1960 to 1981, NCI collected and screened approximately 
35,000 plant species. The Pacific Yew (Taxus brevifoli) was included in this screening program, 
leading to the identification of paclitaxel, commonly known as Taxol®, one of the most important 
chemotherapeutic agents against breast and ovarian cancers (Nicolaou et al., 1994). 
Camptothecin, isolated from the tree Camptotheca acuminate, is also an anti-cancer drug used in 
traditional Chinese medicine, and discovered as a result of the NCI screening program (Wall et 
al., 1966; Wall and Wani, 1996). These two drugs alone represent one third of the drugs used 
globally to inhibit growth of malignant cells (Jones, Chin and Kinghorn, 2006).  
Another method of amassing a large chemical library is through the creation of a 
combinatorial library. Combinatorial libraries are created through the reaction of a small number 
of starting compounds with a larger number of reagents, and subsequently recycling the products 
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from each iteration with the same reagents, exponentially increasing the number of compounds 
(Lam, Lebl and Krchnak, 1997). This method was considered easier than isolating natural 
products. However, this method has not met expectations, and there are questions regarding the 
effectiveness of combinatorial libraries in drug creation (Horton, Bourne and Smythe, 2003). To 
date, only one de novo combinatorial compound in 25 years has been developed into a drug, 
Nexavar, used in kidney cancer treatment (Grabowski, Baringhaus and Schneider, 2008).  
 
1.5.4 Why Are Natural Products ‘Privileged’ Structures? 
Several studies have thoroughly compared the characteristics of natural products with 
that of synthetic compound libraries in an attempt to better understand the advantages of 
compounds from nature. The failure of combinatorial libraries has been attributed to the lack of 
biological relevance of the synthetic scaffolds (Kaiser et al., 2008). In contrast to synthetic 
compounds, natural products are considered ‘privileged’ structures because they were created 
with the ability to bind to biological macromolecules (Koehn and Carter, 2005; Firn and Jones, 
2003). Spatial structure and fold types of proteins are fairly conserved throughout evolution; 
natural products may have the ability to bind to a variety of protein domains and folding motifs 
across many species and have a range of functions (Koch et al., 2004; Bon and Waldmann, 
2010).   
Koehn et al. (2005) explored the chemical scaffolds and pharmacologic properties of 
natural products to understand the physical differences that may be the basis of ‘privileged 
structures’. Their paper points out that natural products were typically shown to have a greater 
number of chiral centers and increased steric complexity compared to either synthetic drugs or 
those compounds produced in combinatorial libraries. Natural products were also found to have a 
broader distribution of molecular properties (i.e. molecular mass, octanol-water partition 
coefficient and diversity of ring systems). 
 
  
! 16 
1.6.  Using Ethnobotany to Navigate Chemical Space 
 
 While nature is a rich source of novel chemicals with pharmacological potential, 
identifying natural products with biological activity is fraught with difficulties (Spellberg et al., 
2004). The organic chemist Friedrich Wöhler described organic compounds: 
 
“Organic chemistry [is] enough to drive one mad. It gives me the impression of a 
primeval forest full of the most remarkable things, a monstrous and boundless 
thicket, with no way of escape, into which one may well dread to enter."  
 
Wöhler correctly alluded to the large number of compounds that exist in nature, the marvelous 
diversity of their structures and the trepidation many researchers feel when trying to make sense 
of the vast chemical space. Notwithstanding the obvious advantage of natural products, it is not 
feasible to sample all existing natural compounds. There is a need for a focused approach to 
identify a compound or compound class relevant to a particular biological phenomena (Bon and 
Waldmann, 2010). One such method is the use of ethnobotany, a term coined by the American 
botanist William Harshberger, to describe the study of how different human populations use 
plants, including but not limited to the use of plants as medicine (Heinrich and Bremner, 2006).  
Some prominent examples of medicinal plants that have been developed into drugs are: 
the previously mentioned Pacific Yew (Taxus brevifolia) which was used by American Indians 
to treat arthritis and other ailments and Artemisia species, which are popular medicinal plants in 
many parts of the world that have been developed into treatments of malaria (Wani et al., 1971; 
Tan, Zheng and Tang, 1998). In fact, it has been noted that among all the drugs that have plant 
origins, 77% of the plants were used in traditional medicine (Rollinger, Langer and Stuppner, 
2006). The means by which these and other plants were originally selected by humans for 
treating various illnesses are not known (Fabricant and Farnsworth, 2001). The treatment choices 
in traditional medicine are complex and involve social, cultural, historical and linguistic 
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considerations that are not fully understood by those outside the culture (Heinrich and Bremner, 
2006). Furthermore, many ethnobotanical studies describe the uses of medicinal plants based on 
discussions with a shaman or herbalist who combines the roles of pharmacist and medical doctor 
with cultural and religious beliefs. Many of these herbalists believe that, along with divine 
elements, a potpourri of ingredients serves to provide the overall activity and clinical efficacy 
cannot be attributed to a single ingredient (Phillipson, 1994).  
The fusion of the scientific and the spiritual causes many laboratory-based scientists to 
view ethnobotany as an exotic and exciting area, but not one they consider to be of relevance to 
their research (Heinrich and Bremner, 2006). Other scientists regard traditional belief systems as 
magic or mysticism, thus lacking credibility (Fabricant and Farnsworth, 2001). Even those 
scientists that fall in the middle of the spectrum have fundamental differences with the traditional 
holistic approach to medicine because they believe that traditional remedies should be 
investigated to identify a single active ingredient (Wang et al., 2012). No matter where on the 
scale one may fall, it is agreed that the continued use of certain plants over centuries empirically 
demonstrates that they contain compounds with biological activity in humans. According to the 
WHO, almost 65% of the world’s population has incorporated traditional remedies in to their 
primary modality of medical care (Fabricant and Farnsworth, 2001). 
  The example of Taxol® and other drugs demonstrate an important fact about the 
contribution of ethnobotany: the traditional uses of a plant are not always germane to the modern 
therapeutic indication for the derived drugs (Durzan, 2009). Therefore the knowledge obtained as 
result of an ethnobotanical study should not be limited to the traditional uses of the plant 
(Heinrich and Bremner, 2006). The information regarding indigenous uses of plants can be used 
as a tool to help scientists navigate ‘the boundless thicket’, steering them in the direction of 
plants that are of pharmacological value (Jones et al. 2006).   
 
  
! 18 
1.7. South Africa: A Case Study for Plants Used Ethnobotanically in the Treatment of 
Tuberculosis  
 
Even when ethnobotanical information is used to systematically explore plants with 
pharmacological potential, there is still a chemical space too vast to completely explore. 
Researchers often limit investigations of ethnobotanically used plants to a specific region of the 
world. An ideal location would be a region known for its plant diversity and one that has a 
population adept at using these plants as medicine. The country of South Africa is particularly 
suited for such an inquiry into ethnobotanical treatments for TB, due to not only its biodiversity, 
but also its high rate of TB infection. 
 
1.7.1 Plant Species Diversity 
South Africa is the third most biologically diverse country on earth, with some 18,625 
vascular plant species within its boundaries (comprising 7.5% of the world's total), of which 80% 
are endemic (Kepe, Saruchera and Whande, 2004; Cowling and Rundel, 1998). This plant 
diversity and endemism is largely attributed to the diverse ecological conditions of southern 
Africa relative to the rest of the continent. South Africa is divided into nine biomes, with a wide 
range of ecosystems, including areas that range from extreme desert to subtropical and have 
extreme heterogeneity of geology, soils and elevations (Egoh et al., 2009). South Africa is home 
to the succulent Karoo biome, which has the highest diversity of succulent plants in the world 
and is the most species-rich semi-desert. Also of note is the summer rainfall Grassland biome 
that is home to a wealth of species limited to southern Africa (Mucina and Rutherford, 2006). 
This diversity of biomes is remarkable for a relatively small country of 471,011 sq mi, roughly 
twice the size of Texas. 
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1.7.2 Ethnobotanical Knowledge  
The diversity of plant species in South Africa is equally matched by a rich cultural 
diversity. Each of South Africa’s ethnic groups has developed a tradition of using plants in the 
treatment of disease for more than four centuries. Black Africans account for 79% of the total 
population, with the largest ethnic groups being the Zulus, the Xhosa, the Northern Sotho and the 
Southern Sotho (McLaughlin, 2007). White South Africans, who are mainly descendants of 
British and Dutch settlers, are the second largest group. The remainder of the population identify 
themselves as mixed race at 8.9%, and Asian descendants of Indian, East Indian and Chinese 
indentured laborers at 2.5%. The tradition of using plants as medicine by all South Africans is 
still prevalent today. Currently, over half of the population use traditional healers as their 
primary source of care (van Wyk, 1997). Traditional healers have considerable stature and are 
formally recognized by the government alongside national healthcare providers (van Niekerk, 
2012). 
 
1.7.3 High Incidence of Tuberculosis 
In addition to a rich history of using plants in the treatment of disease, South Africa also 
has one of the highest incidences of TB in the world (Dye, 2005). This is the unfortunate result 
of political and social norms that combined to create circumstances that promotes the spread of 
TB. Centuries of colonialism, followed by nearly fifty years of racial segregation resulted in 
overcrowded squatter settlements, the creation of a migrant labor class, and underdeveloped 
health services for black South Africans (Karim et al., 2009). When migrant workers, who 
temporarily lived in the cities, made regular visits to families in rural homelands, they spread TB 
and sexually transmitted diseases across the country. South Africa has 400,000 new cases of 
tuberculosis each year and in some regions over 10% of the cases are MDR-TB strains (Karim et 
al., 2009). The TB crisis is exacerbated by the HIV epidemic because it creates an immune-
suppressed population that is particularly vulnerable to infection and unable to combat 
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replication of Mtb. South Africa also has a rich history of using plant medicine in the treatment 
of diseases including TB.  
 
1.8. Challenges in Natural Products Research 
 
 While nature is a potential source of new compounds with pharmacological properties, 
identifying natural products with specific biological activity is fraught with difficulties. There are 
technical barriers that accompany any natural products research effort. Taxol® can be considered 
a success story, demonstrating how ethnobotany can assist in the identification of the biological 
resources to be found in nature. However, it also can be considered a cautionary tale, and 
examples from its discovery process will be used to illustrate some of the difficulties in natural 
products research. 
 
1.8.1 The Plant Extraction and Fractionation Process 
The investigation of plants for biological activity is a lengthy, multi-step extraction 
process followed by the identification of active compounds required to investigate a plant for 
biological activity (Bueno Sanchez and Kouznetsov, 2010). The steps of a plant extraction have 
changed little since being described in the first issue of the Journal Plant Physiology almost a 
century ago (Newton, Brown and Martin, 1926). While there are variations, the main steps 
involve the drying or lyophilization of the plant material, sequential extraction with solvents of 
different polarity and evaporation under vacuum pressure. This process is not easily modified to 
fit a high throughput model, making it unattractive for time sensitive projects and/or profit driven 
models.  
The active compound(s) of a plant extract are identified via bioassay-guided 
fractionation, where the biological activity of an extract is assessed after alternating steps of 
fractionation and biological testing. The fractionation steps can be chemical and/or 
chromatographic. Fractionation is labor intensive and requires large quantities of plant material 
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because each step of the process significantly reduces the material yield. The initial isolation of 
the active component from the pacific Yew took four years; subsequent isolations took nine 
months to a year (Cragg et al., 1993). Fifteen thousand pounds of bark were required to yield 1.3 
kg of the Taxol®. In 1991 alone, over 1.6 million pounds of bark was harvested for Taxol® 
production, causing concern about the survival of the Pacific Yew population (Wall and Wani, 
1995).   
 
1.8.2 Access and Supply of Plant Material 
Population growth, urbanization and the unrestricted collection of medicinal plants from 
the wild has resulted in the over-exploitation of some species (Zschocke et al., 2000). There are 
concerns about the loss of biological diversity and the continued availability of medicinal plant 
resources (Hamilton, 2004). Ethnobotanist Walter Lewis made the following comment that is 
still true today (Lewis and Elvin-Lewis, 1995): 
 
 “Serious dangers exist for the survival of such peoples and their cultures, and the 
ecosystems which nurture them and provide Western and traditional medicines 
with novel plant products for human well being everywhere.”  
 
Human behavior is believed to have caused the current and sixth known period of mass 
extinction with 8% of all plants threatened with extinction, including 4000 species used in 
traditional medicine (Rahbek and Colwell, 2011; Schippmann, Leaman and Cunningham, 2002).  
While one solution is large-scale cultivation, it is not viable in the short term to supply the 
quantities of plants required for both research and traditional uses (Zschocke et al., 2000). There 
are few cultivated medicinal plants. China is probably the country with the greatest cultivation of 
medicinal plants.  In South Africa, 99% of those plants sold for traditional medicine are collected 
from the wild (Hamilton, 2004).  
! 22 
There are also restrictions to the availability of plant material due to intellectual property 
concerns. At the moment, most laws and regulations regarding intellectual property rights are not 
able to protect traditional knowledge and indigenous peoples (Kartal, 2007). This is because it is 
difficult to define intellectual property with regards to plant knowledge and to establish 
ownership (Kartal, 2007). Traditional knowledge of the uses of plants can be based on years, 
perhaps millennia, of use and experimentation. In the past, scientists, research institutes and 
commercial enterprises have taken samples of without the proper permission or on ethically 
unacceptable terms. It is often argued by proponents of indigenous rights that scientists or 
pharmaceutical companies cannot claim to be the sole inventors of any resulting product 
(Hamilton, 2004). Unfortunately, without a practical solution, some countries have reacted to the 
threat of theft of intellectual property by creating such tight access restrictions that they are likely 
to cause setbacks to research (Gupta, Gabrielsen and Ferguson, 2005). Many researchers afraid 
of a legal battle have avoided this type of research. 
 
1.8.3 Difficulties and Solutions in Compound Identification 
 The occurrence of natural products as a mixture of structurally related compounds has 
historically made the isolation and identification of active compounds a challenge (Koehn and 
Carter, 2005).  In the past, the identification of new natural products relied on the ability to 
isolate the compound of interest with a high degree of purity (Jaroszewski, 2005). Nuclear 
magnetic resonance (NMR) could only be used for structural identification after successful 
separation of sufficient amounts of a given compound. However, technological advances have 
made it so that less compound is needed and that complete separation is no longer necessary 
(Koehn, 2008). 
There have been technological advances that have made the identification of compounds 
easier. Most notably, progress in NMR has allowed for the elucidation of the structure of 
compounds that would previously not have been possible. First, there have been improvements 
in the sensitivity of NMR through the use of stronger magnetic fields. This has dramatically 
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reduced the amount of material needed for structural analysis. Secondly, the use of pulse 
sequences in NMR can be used to produce diagnostic signals that provide scalar (through bond) 
and dipolar (through space) molecular connectivity correlations that can be used to determine the 
structure of the compound (Eisenreich and Bacher, 2007). To date, thousands of pulse sequences 
have been developed; each designed to ascertain a different type of physical information about a 
compound. Thirdly, the application of these technologies has led to the development of 
techniques that make it possible to identify compounds in increasingly complex mixtures 
(Schroeder et al., 2007). Although the determination of structures is technically challenging and 
resource intensive, the aforementioned advances make compound identifications possible that 
previously were not. 
 
1.9. Plant-derived Compounds with Anti-mycobacterial Activity: Limitations in Previous 
Studies 
 
A survey of the literature suggests that there are approximately of 400 reports of plants of 
global origin, and thousands of isolated phytochemicals that have been tested in some capacity 
for anti-tubercular activity (Newton et al., 2000; Pauli et al., 2005). The discussion to follow will 
highlight the limitations of these studies and consider improvements that can be made for future 
inquiries. More consideration is needed in the following areas: design and implementation of the 
biological assays used to evaluate the plant extracts and compounds, addressing the issue of 
latent TB and the inclusion of target analysis and structure activity relationships (SAR) studies 
(Thomson et al., 2004).  
 
1.9.1 Biological Assays: Mycobacterium species 
The genus Mycobacterium is divided into fast-growing species and slow-growing 
species. Most slow-growing members of the genus, including Mtb, are pathogenic to humans 
(McGaw, Lall, Meyer and Eloff, 2008). Research involving Mtb requires the Bio-safety Level 3 
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facilities to safely handle airborne human pathogens (Heifets and Desmond, 2004). Many 
institutions do not have the resources to work with Mtb and as a result choose to work with M. 
smegmatis, a fast-growing species that is non-pathogenic and requires no special safety 
considerations. The results of experiments using fast-growing Mycobacterium species are not 
always an accurate indicator for how effective a compound is against Mtb (McGaw et al., 2008). 
The better alternative is to use M. bovis BCG which is closely related in genetic composition, 
pathogenic to cattle but not to humans, and only requires a class 2 biosafety cabinet, which most 
institutions can accommodate (Gutierrez et al., 2005). The drawback of work with M. bovis BCG 
is that it is a slow-growing bacterium, with a doubling time of 15-20 hours; many experiments 
require a minimum of two weeks to obtain results.  
 
1.9.2 Addressing the Challenge of Latent Tuberculosis Infections 
The goal of current TB research is to identify antibiotics that are effective against non-
replicating Mtb in order to reduce the duration of therapy. Such a compound would have to be 
effective under the growth conditions that Mtb encounters in the host. Those conditions include, 
but are not limited to, a reduced pH, the presence of RNI, decreased oxygen and limited 
carbohydrate availability. Past research into anti-mycobacterial compounds derived from plants 
still uses screening methods that involve in vitro conditions that sustain rapid growth and 
assaying for inhibition of that growth (Nathan 2004). Subsequently, most antibiotics, including 
those currently used to treat TB, target biosynthetic processes that bacteria need to replicate and 
increase their biomass. Only two of the first-line treatments for TB, rifampicin and 
pyrazidamide, have any efficacy under conditions that prevent the bacteria from replicating 
(Somoskovi, Parsons and Salfinger, 2001). New assays are available and have been used by 
microbiologists. However, it has not permeated into natural product studies (Parrish, Dick, and 
Bishai, 1998; Wayne and Sohaskey, 2001). Furthermore, no publications were found that 
discussed the inhibitory activity of plant extracts against non-replicating Mtb.  
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1.9.3 Structure Activity Relationships (SAR) Studies 
Drug discovery efforts begin with compounds that have demonstrated inhibition in the 
micro-molar range progress in drug discovery efforts (Nathan, 2004). This parameter eliminates 
many plant-derived compounds from consideration since few isolated principles have activity 
below the micro-molar range. To improve inhibitory activity, structure activity relationship 
(SAR) studies are needed. The process involves a systematic comparison of structural 
modifications to active molecules in relation to their biological activity. SAR studies have the 
potential to create structural analogues whose inhibitory activity is increased by two orders of 
magnitude when compared to the original structure (Pauli et al. 2005). SARs can also be used to 
improve biological activity such as membrane permeability or increase solubility (Terstappen, et 
al., 2007). Camptothecin, an anti-leukemic and anti-tumor drug, progressed in the drug discovery 
process because of SAR results (Wall and Wani, 1995). Clinical trials were originally restricted 
because of insolubility, but extensive structure-activity studies identified analogs of 
camptothecin with equal or better anti-tumor activity and with better solubility properties. 
Unfortunately, most natural products research projects do not include SAR studies (Pauli 
et al., 2005). SAR for natural products can be arduous. It can take a team of medicinal chemists 
years to make modifications that improve potency due to the complex structure and multiple 
chiral centers of many natural products (Nathan, 2004). In lieu of these investigations, inferences 
can be based on comparisons of the biological activity of available compounds that are in the 
same structural class (De Souza et al., 2007). These conclusions are limited, especially if they are 
based on heterogeneous protocols.  
 
1.9.4 Investigation into the Mechanism of Action 
To adequately address the problem of resistance, compounds with new mechanisms of 
action are needed. However, with few exceptions, analysis of molecular targets or intercellular 
mode of action is almost completely absent from natural product studies (Pauli et al., 2005). One 
approach to identifying the target of antibacterial compounds with an unknown mode of action is 
! 26 
to isolate spontaneously resistant mutants and identify the genetic basis of resistance (Mills, 
2006). Recently developed genetic tools are facilitating this line of inquiry through improved 
bioinformatics and automated genome sequencing (Bansal, 2005). With these tools it is possible 
to identify a gene that confers resistance and develop an understanding about its function. 
Another approach is the use of DNA microarray analysis to look at the transcriptional response 
of the bacteria to the drug (Rosamond and Allsop, 2000). Comparing the differential expression 
of genes as a result of exposure to a compound of interest can help identify the genes and 
pathways that are important for bacteria to persist when exposed to an inhibitor (Waddell and 
Butcher, 2007).  
Investigations into the mode of action can also serve additional purposes. These studies 
can also be used to augment inhibitory data. There was not much initial interest in Taxol® 
because it only had modest activity and was insoluble in water (Kingston, 2007). Taxol® only 
advanced through clinical trials after Susan Horwitz discovered its mechanism of action (Schiff, 
Fant and Horwitz, 1979). The identification of a molecular target can be used in conjunction with 
SAR to make calculated changes to the compound structure. The use of the molecular target is 
the best way to rationally optimize a compound.  
 
1.10 Conclusion 
 
New drugs are needed in the treatment of TB that address the challenge of non-
replicating bacteria, and that improve treatment of MDR-TB and XDR-TB. The diversity of 
natural products found in plants represents a vast resource in the search for new anti-TB 
compounds. Plants have been utilized as medicines throughout history. The ethnobotanical 
knowledge underlying this use was thoroughly gathered through trial and error, the results of 
which have been passed down through generations. Today, this information can be applied to TB 
drug discovery. Plants can provide active compounds that are leads suitable for optimization by 
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medicinal and synthetic chemists. Even more than synthetic compounds, natural products contain 
diverse structures that have been shown to be active in drug discovery efforts. 
This project uses the ethnobotanical knowledge of South African medicinal plants to 
identify plant-derived compounds with activity against replicating and non-replicating Mtb. 
Compounds of interest can be identified using an interdisciplinary approach that involves 
identifying plants of interest, preparation of plant extracts, biological screening using 
pharmacologically relevant assays. While the investigation of natural products presents many 
challenges, it is a worthwhile effort that can provide new and urgently needed treatment options 
for TB. 
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CHAPTER 2 
Collection and Testing of South African Medicinal Plants 
 
2.1 Overview 
The plant diversity of South Africa has great potential to offer metabolites that may be 
effective against Mycobacterium tuberculosis (Mtb). This chapter describes how South African 
medicinal plants were selected and evaluated for inhibitory activity against Mtb. Two biological 
assays were used to evaluate plant extracts, one that assesses inhibitory activity against 
replicating Mtb and another that evaluates the inhibitory activity against Mtb that is in a non-
replicating state. Eradicating non-replicating Mtb is one of the major challenges in the treatment 
of tuberculosis (TB). While some of the plants tested have been previously investigated in some 
capacity for antimicrobial activity, none have been tested for activity against non-replicating 
Mtb. The results of this study indicate that the plant Warburgia salutaris demonstrates inhibitory 
activity against Mtb under both test conditions.  
 
2.2 Introduction   
 
Ethnobotanical knowledge of medicinal plants has been successfully used to identify 
plants with pharmacological potential. This study focuses on plants with inhibitory activity 
against Mtb. Past screening projects and current pharmaceutical drugs have shown that plants 
used in traditional medicine have a higher percentage of pharmacologically active compounds 
than plants selected at random (Hostettmann et al., 1996). Among all the drugs that have plant 
origins, 77% of them were used in traditional medicine (Rollinger, Langer and Stuppner, 2006). 
Since it is not plausible to test all medicinal plants, this project limited the investigation to South 
Africa, a country known for its plant diversity and with a population that has a strong tradition, 
which persist today, of using these plants in the treatment of disease. 
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2.2.1 Ethnobotany in South Africa 
The African continent is believed to have the oldest known human settlements and a 
strong tradition of using plants as medicine (Vrba, 1996). However, the knowledge of African 
plants used in the treatment of disease is limited. First, the study of African medicinal plants was 
traditionally an oral tradition and is not as well documented as some other cultures, such as 
Ayurvedic or Chinese traditional medicine (Makunga, 2008). Secondly, the use of medicinal 
plants is situated within larger cultural frameworks that are often poorly understood (Iwu, 1993). 
The prevalent image of the African medicine man is that of a witch doctor muttering 
incomprehensible incantations, while the reality is far more complex. The original documents 
that describe the use of plants by African ethnic groups were prepared by Europeans and these 
compilations often do not reflect cultural intricacies. They are also filtered through the cultural 
perspective of each author; inevitably information has been omitted or altered (Makhubu, 1998). 
It is estimated that between 12 and 15 million South Africans use approximately 3000 
plant species in the treatment of disease (van Wyk, van Oudtshoorn and Gericke, 1997). 
Although more recent data is not available, by the end of the 1990’s the total number of 
traditional healers in South Africa was estimated to be 350,000, outnumbering those who 
practice modern medicine (Kale, 1995; Peltzer, 2009). Traditional medicinal practices in South 
Africa, like the rest of the continent, have been dominated by oral tradition (Light et al., 2005). 
Early documentation of the uses of plants as medicine date back to the late nineteenth century 
(Hutchings et al., 1996). These early contributors were often missionaries, anthropologists, 
linguists and botanists. Information in these original records is sparse and does not always 
include details about the dosage, preparation methods, and plant identifications are not reliable 
(Hutchings et al., 1996). 
Because documentation is incomplete, this study would have benefited from new 
discussions with traditional healers that currently use plants in the treatment respiratory ailments. 
Unfortunately, the existing policies in South Africa regarding medicinal plants are not adequate 
to ensure the equitable sharing of benefits that may result from the use of ethnobotanical 
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information (Makhubu, 1998). Also, there is no well-defined way to assign ownership to the 
knowledge and obtain informed consent. Without a way to protect the rights of prospective 
volunteers, this project did not include any surveys or discussions with people who practice 
traditional medicine. The focus, therefore, was only on those plants that had been discussed in 
previously published reports and were considered information already in the public domain.   
 
2.2.2 The Plant Selection Process 
Plants were selected for this study primarily based on their traditional medicinal usage as 
described in books and monographs. Due to the lack of documentation, two ethnobotanical 
inventories were heavily relied on to select plants for this study. The first was the reference text, 
“The Medicinal and Poisonous Plants of Southern and Eastern Africa” by Watt and Breyer-
Brandwijk (1962), which has become the canonical documentation of indigenous botanical 
medicines of southern and eastern Africa, originally published in 1932. The second was the book  
“Medicinal Plants of South Africa”, a monograph by van Wyk et al. (1997), which is a 
photographic guide to the most commonly used South African plant medicines. These two 
books, as well as peer- reviewed journals, were surveyed for any plant described in the treatment 
of respiratory ailments including cough cold, flu, bronchitis and tuberculosis. These broad 
criteria were used because it could not be assumed that TB was being accurately diagnosed and 
there was no way to verify the correctness of translated disease names.  
Another consideration in the selection of plants is that the traditional uses of a plant are 
not always germane to the modern therapeutic indication for the derived drugs (ie. Taxol®). With 
this in mind, two species were included in this study, not because of their reported anti-therapies, 
but because they were readily available and of interest to other researchers at the University of 
Cape Town where the plant extraction for this research was taking place. These plants had been 
only previously reported in traditional treatments of malaria, and laboratory investigations into 
their biological activity were limited.  
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After a review of the literature, there were two factors that determined which plants were 
ultimately collected and used in this study. First, there was concern regarding the conservation 
status of the medicinal plants. Due to over-harvesting and habitat destruction, many valued 
indigenous plant species are now near extinction (Williams, Balkwill and Witkowski, 2000) and 
their collection is restricted. Secondly, some plants would have required extensive and costly 
travel to collect and were ultimately omitted from the study. Fortunately, with the assistance of 
Pakamani Xaba, botanist and curator at Kirstenbosch Botanical Garden in Cape Town, 
permission was given to collect most of the plants from the Kirstenbosch Botanical Garden. The 
South Africa National Biodiversity Institute has established small-scale cultivation of many 
medicinal plants within the botanical garden to promote the sustainable use and conservation of 
the country’s plant biodiversity (Driver, 2005).  
The logistics of transporting plant samples from South Africa into the United States also 
influenced the number of plants that were included in this study. Permits are required from the 
USDA Animal Plant Health Inspection Service for shipments of plant parts into the United 
States. In South Africa it would have also been necessary to obtain ‘Phytosanitary Certificates of 
Inspection’ issued by the National Plant Protection Service of South Africa. To circumvent this 
regulatory labyrinth, all collected plant parts were processed in South Africa and the dried plant 
extracts were shipped to Cornell University. While this facilitated the delivery of plant samples, 
it introduced a new time constraint. The laboratory facilities at the University of Cape Town had 
solvents of unknown purity that required simple, but time demanding, purification before they 
could be used for plant extractions. Ultimately, nine plants were successfully extracted and 
shipped for testing.  
 
2.2.3 Recent Investigations into South African Medicinal Plants Used in the Treatment of 
TB 
A 2008 review by McGaw et al. focuses on South African plants used to treat TB-related 
symptoms and the laboratory investigations into their biological activity. In South Africa, 180 
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plants are reported as used in the treatment of TB related symptoms, broadly defined as 
coughing, chest complaints and other respiratory ailments. McGaw et al. highlight the 
shortcomings of the past studies and this review helps illustrate how this project differs from 
these past studies. 
The McGaw et al. review explains that a major emphasis of the ethnopharmacological 
research in South Africa is to validate traditional remedies. With this goal, most studies stop at 
analysis of crude extracts and do not progress to compound identification; demonstrating any 
inhibitory activity of the plant extract is sufficient to provide some scientific rationale for the 
traditional use. In contrast, the goal of the current project is not to validate traditional practices. 
Rather, it is to identify a compound or compound class that should be considered further in the 
development of new anti-TB therapies.  
Past studies into the inhibitory activity of plant extracts commonly report minimum 
inhibitory concentrations (MIC) as high as 10 mg/mL. MICs are often calculated as the lowest 
concentration of drug that inhibits growth by at least 99% (Andrews, 2001). In natural products 
research initial MICs refer to crude extracts that likely contain hundreds of compounds, of which 
the active constituents represent only a small portion. Pharmaceutical drug development usually 
begins with pure compounds that have MICs that are measured in nanogram concentrations 
(Nathan, 2004). This restriction cannot be easily applied to natural products research. Plant 
extracts are complex chemical matrices that contain many compounds that do not contribute to 
the activity. Therefore the threshold for activity for plant extracts should understandably be more 
lenient. Additionally, isolated naturally occurring compounds have not had the benefit of being 
modified by medicinal chemists, who can increase the inhibitory activity by several orders of 
magnitude. While the threshold of activity for plants should be more than standards applied to 
pharmaceutical drugs, the parameters used by ethnobotanist must be more stringent than many 
previous studies (McGaw et al., 2008). 
Only 30% of the plants documented in the McGraw study as being used in the treatment 
of respiratory ailments have been tested for activity against any Mycobacterium species. 
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Additionally, most investigations involve testing against fast-growing, non-pathogenic species, 
the results of which are not always an accurate indicator for how effective a compound will be 
against Mtb (McGaw et al., 2008). In the host, immune activation creates an heterogeneous 
environment that causes Mtb to enter a non-replicating state characterized by growth arrest and 
altered metabolic activity (Flynn and Chan, 2001). Many of the conditions that induce latency 
are believed to include, but may not be limited to, any combination of the following: low pH, 
reduced carbon availability, hypoxia and the presence of reactive nitrogen intermediates (Wayne 
and Sohaskey, 2001). It is within the context of these conditions that anti-TB compounds need to 
function. To date, no plant extracts have been tested under the conditions that prevent Mtb from 
replicating. 
 
2.3 Ethnobotanical Description of Tested Medicinal Plants 
 
• Artemisia afra Willd. (Asteraceae) is a highly aromatic perennial shrub, widely distributed 
throughout South Africa. Artemisia afra is one of the most widely used traditional medicines in 
South Africa. It is used to treat coughs, colds influenza, fever, and gastrointestinal disorders (van 
Wyk et al., 1997; Scott, Springfield and Coldrey, 2004). Often fresh leaves are inserted directly 
into the nostril or the leaves are boiled in water and the fumes inhaled. The volatile oil of A. afra 
contains camphor and thujone as major constituents (Graven et al., 1992). Ethanol extracts from 
A. afra have been shown to inhibit the growth of the non-pathogenic Mycobacterium smegmatis 
at 1.56 mg/mL (Mativandlela et al., 2008).  
 
• Caesalpinia volkensii (Caesapiniaceae) occurs in forests and in tropical regions of southeast 
Africa (Bosch, 2008).  Herbalists prescribe a hot aqueous extract of the leaves or root bark to 
treat malaria, diarrhea, and to fight pain during pregnancy (Njoroge and Kibunga, 2007). 
Aqueous and dichloromethane extracts of C. volkensii have been shown to be active against 
chloroquine–resistant and chloroquine-sensitive strains of malaria (Kuria et al., 2001). While this 
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plant is not commonly used to treat respiratory ailments, it was included in this study because it 
was of interest to many researchers at the University of Cape Town and there are very few 
laboratory investigations into its biological activity.  
 
• Mentha longifolia (L.) Huds. (Lamiaceae), also known as wild mint, is a perennial herb of 
temperate Europe and North Africa. While it is not native to South Africa, it is grown there for 
its therapeutic uses. All parts are highly aromatic with a strong mint smell. The volatile oils that 
contain the monoterpenoids menthol and methone have been used as a decongestant and to treat 
many respiratory ailments including coughs, colds, and asthma (Oyedeji and Afolayan, 2006; Al-
Bayati, 2009). It is also used for headache, fever, and indigestion (van Wyk et al., 1997). 
  
• Polygala fruticosa Berg. (Polygalaceae) is a shrublet less than 0.5m in height and known for its 
attractive purple flowers. The plant occurs along the costal parts of the country in three 
provinces: Western Cape, Eastern Cape and KwaZulu-Natal (Levyns, 1955). Various parts of the 
plant are used in preparing treatments for a wide variety of ailments including tuberculosis, poor 
circulation, gonorrhea and sinusitis (van Wyk et al., 1997). The unusual coumarin, frutinone, has 
been isolated from the plant and has been shown to have antifungal activity (Di Paulo et al., 
1989). 
 
• Rhamnus staddo (Rhamnaceae) is primarily found in the eastern parts of Africa and is used 
primarily in the treatment of malaria. In laboratory investigations, extracts prepared from the leaf 
and bark of R. staddo showed significant antimalarial activity against chloroquine resistant 
Plasmodium berghei (Muregi et al., 2007). This plant was included in this study because 
researchers at the University of Cape Town were investigating its anti-malarial properties and 
there are very few laboratory investigations into its biological activity.  
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• Syzygium cordatum Hochst. ex C. Krauss subsp. cordatum (Myrtaceae) is a medium sized tree 
that can grow up to 15 meters in height. This plant has wide distribution in the eastern and 
northeastern parts of South Africa (Palmer and Pitman, 1972). The thick bark and occasionally 
the leaves are used to treat stomach complaints, diarrhea and respiratory ailments including 
tuberculosis, (van Wyk et al., 1997). It has been tested for inhibitory activity against fifteen 
gram-negative and gram-positive species. The acetone and methanol extracts of the stem bark 
and leaves had MICs varying between 0.31 and 6 mg/mL (Samie et al., 2005).  The ethanol 
extract of the leaves demonstrated inhibitory activity against the non- pathogenic M. smegmatis 
at concentrations of 6.25 mg/mL (Mativandlela et al., 2008). There have been no additional 
studies into its activity against pathogenic Mycobacterium.  
 
• Tarchonanthus camphoratus L. (Asteraceae) is an evergreen shrub or small tree. The 
trichomes on the leaves give the leaves a greyish appearance. Tarchonanthus camphoratus has a 
wide distribution across southern and east Africa and it is found in almost every part of the South 
Africa (Palgrave, 2002). Traditionally, the leaves and twigs are used to prepare aqueous extracts 
to treat a wide variety of diseases including: abdominal pain, headache, asthma, bronchitis, and 
inflammation (Watt and Breyer-Brandwijk, 1962). Laboratory investigations have determined 
that the active ingredients are monoterpenes, a high percentage of which are oxygenated 
monoterpenes; fenchol, cineole, terpineol. These compounds have been shown to have 
antibacterial activity against gram-negative and gram-positive bacteria (Matasyoh et al., 2007).  
 
• Tulbaghia violacea var. violacea Harv. (Alliaceae), also known as wild garlic, is a bulbous 
plant with narrow hairless leaves. The plant has limited distribution in the eastern parts of the 
country in the provinces of Easter Cape and Southern Kwa-Zulu Natal. The bulbs and leaves are 
the primarily used in the traditional remedies for stomach ailments, fever, colds, and 
tuberculosis. Studies have shown that extracts of this plant exhibit antibacterial and antifungal 
activity (Kubec, Velisek and Musah, 2002).  When the extract of T. violacea is applied to the soil 
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of plants that are prone to infections by the fungal pathogens Botrytis cinerea, Pythium ultimum 
and Rhizoctonia solani, there was an increasing plantlet survival (Lindsey and Van Staden, 
2004). The plants in the Alliaceae family, including true garlic, Allium sativum, are generally 
characterized by the presence of low molecular mass sulfur compounds, such as alliin, which 
have also been isolated from T. violacea (Burton and Kaye 1992).  
 
• Warburgia salutaris (Bertol. f.) Chiov. (Canellaceae) is a small tree, 5-10 m in height but 
reaching 20 m in some areas. Its medicinal uses date back several centuries, and it is listed as one 
of the plants traded when Arab dhows first reached the coast of East Africa (Hollmann, 1996). 
Warburgia salutaris has been reported in the treatment of over a dozen ailments. It is used in 
Zulu and Xhosa medicine for the treatment of venereal diseases, headache and gastric ulcers (van 
Wyk et al., 1997). The Venda people in South Africa use the plant to treat sores and ulcers 
(Mashimbye, Maumela and Drewes, 1999). A tea is prepared and used for respiratory ailments 
including colds, congestion, influenza, and other chest complaints. A dried powder is applied to 
sores (Rabe and van Staden, 1997). There are laboratory investigations into the biological 
activity of this plant, including two studies into the anti-mycobacterial properties of the plant. 
These studies showed that dichloromethane (DCM) extracts have inhibitory activity against 
replicating Mtb and M. bovis BCG (Clarkson et al., 2007; Madikane et al., 2007). This will be 
discussed in detail in chapter 3. 
  
 
2.4 Methods 
 
2.4.1 Plant Collection 
Plants were collected in September 2007 at the Kirstenbosch Botanical Garden in Cape 
Town with the consent and assistance of Phakamani Xaba, botanist and curator of the Medicinal 
and Useful Plants Garden at the Kirstenbosch National Botanical Garden. Mature bark of 
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Warburgia salutaris (Bertol. f.) Chiov. (Canellaceae) is difficult to obtain and a sample of the 
dried, macerated bark, previously harvested at the Silver glen Nursery in Durban June 2002, was 
provided by Dr. Peter Smith at the University of Cape Town, South Africa. Plants were allowed 
to air dry at room temperature until they were extracted. 
 
2.4.2 Plant Extraction 
Plants were extracted using the laboratory facilities of Dr. Peter Smith at the University 
of Cape Town Medical School, South Africa. Plant material was dried in open air and macerated 
using an industrial blender. Powdered plant material was extracted sequentially using solvents of 
increasing polarity (dichloromethane, ethyl acetate, and methanol) over a period of 72 hours with 
agitation at room temperature. This extraction procedure does prevent the possibility that some 
monoterpenes and volatiles may be lost during drying and extraction. Not all plants were 
extracted with all solvents. The extracts were concentrated under vacuum, followed by drying 
under a stream of nitrogen. Dried plant extracts were shipped to Cornell University.  
 
2.4.3 Mtb Bioassay 
The biological assays used to screen the plant extracts were adapted from the procedure 
described by Bryk et al. (2008). Testing of these extracts was performed using the laboratory 
facilities of Dr. Carl Nathan at the Weill Cornell Medical College, in the Department of 
Microbiology. Extracts were tested for activity against Mtb under growth-sustaining and growth-
inhibiting conditions. These biological screens used a lysine-pantothenate auxotroph of the wild-
type Mtb H37Rv strain, Mtb mc26020 (∆lysA∆panCD). This multiple auxotroph was used 
because its reduced virulence makes it suitable for biosafety-level 2 (BSL2) handling, instead of 
the BSL3 facilities required for wild-type Mtb (Sambandamurthy et al., 2002).  
Mtb cells were cultivated in Middlebrook 7H9 broth, pH 6.6-8 with 0.2% glycerol, 0.05% 
Tween 80 and 10% ADN (0.5% BSA, 2% dextrose, 0.85% NaCl) (Larsen, Biermann and Jacobs, 
2007). Experiments were performed using an inoculum consisting of mid- to late-log-phase 
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cultures of Mtb (optical density at 580 nm, 0.5 – 0.8 AU). To assess bactericidal activity, growth 
was assessed in 96 well plates.  Reaction wells were prepared with 98 µL of growth medium and 
100 µL inoculum. The plant extracts to be tested were prepared in DMSO and 2 µL volumes 
were added to reaction well to yield a total reaction volume of 200 µL and a final concentration 
of 200 µg/mL. Rifampicin, an antibiotic currently used in TB treatment, was used as a positive 
control and DMSO, used to solubilize the extracts, and was included as a vehicle control. 
The conditions that cause Mtb to enter a non-replicating state include, but are not limited 
to, low pH, reduced carbon availability, hypoxia, and the presence of reactive nitrogen 
intermediates (Wayne and Sohaskey, 2001). These physiological conditions were simulated in 
vitro to mimic the conditions that Mtb encounters the in macrophages that are believed to 
prevent replication. The experimental conditions are described below. 
 
 Growth inhibiting conditions: Midlog phase cells (A580 0.8–1.0) of Mtb, previously 
grown in growth sustaining media, were prepared in 7H9 at pH 5.5, 0.5 mM nitrite NaNO2 and a 
modified Sauten’s media with butyrate as a carbon source (0.1% NH4Cl, 0.005% ferric 
ammonium citrate) with 10% AN (0.5% BSA, 0.85% NaCl), 0.02% tyloxapol, 0.05% butyrate). 
Each 96 well plate was kept at 37 °C and 1% O2 in environmental chambers (BD Biosciences) 
(Bryk et al., 2008). 
 Growth sustaining conditions: Midlog phase cells (A580 0.8–1.0) were prepared as 
single cell suspensions in 7H9 at pH 6.8. These test conditions include ambient levels of O2 
(20%), pH 6.8, and 7H9 medium enriched with glycerol used as a carbon source. 
 
The inhibitory activity of the plant extracts tested under growth-sustaining conditions was 
determined by measuring optical density (Molecular Devices, SpectraMaxPlus Absorbance 
Microplate Reader) after 7 days. For the growth-inhibiting conditions, following the 7-day 
exposure, killing was assessed by dilution into growth-sustaining media and outgrowth after 10 
days was determined via optical density. 
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2.5 Results and Discussion 
 
Nine different plants, used to prepare a total of nineteen separate extracts, were tested for 
inhibitory activity against Mtb under growth-sustaining conditions. All plant extracts were 
evaluated at a concentration of 200 µg/mL. The selection of 200 µg/mL recognizes that the 
minimum threshold for activity applied to pure compounds may be too stringent. However, even 
at this high concentration, only one extract, W. salutaris, showed greater than fifty percent 
inhibition of growth, (Table 1). The activity of W. salutaris agrees with a previous report by 
Madikane et al. (2007) which states that at 200 µg/mL the DCM extract of the mature bark 
completely inhibits the growth of replicating Mtb. The specific experimental method used in 
their study was not specified. 
The DCM extract of the mature bark of W. salutaris was also the only extract that 
demonstrated inhibition of more than fifty percent under growth-inhibiting conditions, (Table 2). 
Additionally, when the inhibitory activities of all the plant extracts for both test conditions are 
compared, the percent inhibition was either equivalent or higher against replicating Mtb. One 
plant extract, W. salutaris leaves, appeared to have greater inhibitory activity under growth-
inhibiting conditions, with 33% inhibition under growth-sustaining conditions and 42% under 
growth inhibiting conditions. However, subsequent t-test analysis reveals that there was no 
statistically significant difference between the results of the two test conditions.  
  The activity of W. salutaris is particularly notable since, to date, no plant extracts have 
been tested for inhibitory activity against Mtb under growth-inhibiting conditions or any other 
conditions intended to replicate conditions present in the host. This demonstrates the necessity of 
an interdisciplinary effort in natural products research to ensure that plant extracts are evaluated 
using the most relevant bioassays. There are tuberculosis drugs, such as rifampicin and 
pyrazinamide, effective against non-replicating Mtb. However, these drugs have been in use for 
four decades and there is an urgent need for new drugs with new mechanisms of action to 
combat resistance. Subsequent experiments are focused on the identification of those compounds 
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in W. salutaris that were responsible for this activity and gaining insight into the possible 
mechanisms of action.  
  
 
 
Table 2.1. Plant extracts tested for inhibitory activity against Mtb under growth-sustaining 
conditions. Percent inhibition is normalized against the positive and negative controls, RIF and 
DMSO respectively. 
 
Plant Name (Solvent) Percent Inhibition 
A. afra (EtOAc) 0 
A. afra (MeOH) 0 
C. volkensii  (DCM) 8.71 
M. longifolia (DCM) 4.0 
M. longifolia (EtOAc) 14.0 
P. fruticosa (EtOAc) 0 
P. fruticosa (MeOH) 18.0 
R. studdos (DCM) 22.6 
S. cordatum leaves (MeOH) 0 
S. cordatum leaves (DCM) 14.4 
S. cordatum stem bark (DCM) 35.0 
T. camphoratus (DCM) 43.7 
T. camphoratus (EtOAc) 31.4 
T. camphoratus (MeOH) 0 
T. violacea  (DCM) 0 
T. violacea (MeOH) 6.31 
W. salutaris, leaves (DCM) 33.0 
W. salutaris, leaves (MeOH) 0 
W. salutaris, mature bark (DCM) 91.9 
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Table 2.2. Plant extracts tested for inhibitory activity against Mtb under growth-inhibitory 
conditions. Percent inhibition is normalized against the positive and negative controls, RIF and 
DMSO respectively. 
 
Plant Name (Solvent) Percent Inhibition 
C. volkensii  (DCM) 3.3 
M. longifolia (EtOAc) 5.6 
M. longifolia (DCM) 5.6 
P. fruticosa (MeOH) 1.5 
R. studdos (DCM) 16.6 
S. cordatum leaves (DCM) 19.4 
S. cordatum stem bark (DCM) 10.8 
T. camphoratus (DCM) 28.3 
T. camphoratus (EtOAc) 33.7 
T. violacea (MeOH) 0.52 
W. salutaris, leaves (DCM) 42.3 
W. salutaris, mature bark (DCM) 90.6 
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Figure 2.1. Inhibitory activity of South African plant extracts against replicating and non-
replicating Mtb. 
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CHAPTER 3 
Bioassay Guided Fractionation of Warburgia salutaris and Biological Activity of Synthetic 
Drimane Compounds 
 
3.1 Overview 
Nine South African medicinal plants were tested for inhibitory activity against both 
replicating and non-replicating Mtb. The dichloromethane (DCM) extract of the mature bark of 
Warburgia salutaris demonstrated inhibitory activity against Mtb under both test conditions. 
Warburgia salutaris was included in this screen because it is used in South African traditional 
medicine to treat a variety of illnesses, including tuberculosis (TB). To date, no plant extract has 
been tested for inhibitory activity against non-replicating Mycobacterium tuberculosis (Mtb). 
This finding is important because potential new TB treatments are needed that are effective 
against non-replicating Mtb to shorten treatment courses.  
This chapter will describe 1) the method of used to isolate and identify the compounds 
responsible for the biological activity 2) the biological assays used to assess the products of each 
fractionation step and 3) the investigation of synthetic drimane compounds that are structurally 
similar to those compounds isolated from W. salutaris. The result of the bioassay-guided 
fractionation identified the drimane sesquiterpenes class, specifically the compounds 
warburganal and muzigadial, as contributing to the biological activity. Naturally occurring 
drimanes are not readily available in large quantities and it was therefore important to identify 
synthetic analogues for use in subsequent testing. Thirty-one synthetic drimane sesquiterpenes 
were tested at 50 µg/mL and eight had percent inhibitions of greater than 65%.  
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3.2 Introduction 
 
3.2.1. Taxonomy 
The Canellaceae family is a small family of 5 genera. The genus Warburgia is 
exclusively African and includes four species: W. salutaris Berto F. Chiov, W. elongata Verd., 
W. stuhlmannii Engl. and W. ugandensis Sprague. Warburgia salutaris has limited distribution 
and is found in southern Africa (South Africa, Lesotho, Swaziland, Mozambique). The other 
plants of this genus: W. elongata and W. stuhlmannii are found along the East African coastline 
and W. ugandensis is found in the east African highlands of Uganda, Kenya and Tanzania 
(Muchugi et al., 2008). 
There has been some controversy regarding the organization of species within the 
Warburgia genus. In 1956, Verdcourt reported only three species in the genus, W. stuhlmannii, 
W. ugandensis and W. elongata (Verdcourt, 1956). In 1976, W. salutaris was included in the 
genus (Ross, 1976). Other works have debated whether W. salutaris is the same as W. 
ugandensis subsp. ugandensis but the two have been kept separate based on differences in the 
number of ovules and the difference in fruit size (Hollmann, 1996). Warburgia ugandensis has 
30 ovules and fruits up to 5cm in diameter, while W. salutaris has 15-20 ovules with fruits 1.5-
2.5 cm in diameter (Ross, 1976; Verdcourt, 1956). A recent study by Muchugi et al. (2008) 
analyzed the genetic diversity of wild populations of the genus and determined that there is 
considerable similarity between W. salutaris and W. stuhlmannii populations from Tanzania, 
despite their distinct morphological characteristics. Muchugi et al. (2008) speculate that W. 
salutaris and W. stuhlmannii are in fact the same species that have adapted to different ecological 
environments. 
 
3.2.2. Ecology and Conservation of W. salutaris 
Warburgia salutaris is found along the eastern seaboard of South Africa in the 
indigenous forests, the smallest biome in the country, and the recently classified eastern Albany 
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thicket biome  (Mucina and Geldenhuys, 2006). Most forests in South Africa occur as areas no 
larger than 10 hectares imbedded within larger scale biomes (Mucina and Geldenhuys, 2006). 
The indigenous forest in South Africa represents only 0.27% of the total land surface and is the 
country’s second most species-rich biome (Lawes, Eeley and Piper, 2000).  
Warburgia salutaris is threatened due to anthropogenic disturbances of its habitat and the 
widespread medicinal uses of the plant. In 1995, members of the Natal National Parks Board 
found that in all of the naturally occurring localities W. salutaris trees had been debarked and 
there were few mature specimens remaining (Johnson and Scott-Shaw, 1995). Even though this 
plant is considered fast growing with vigorous coppicing ability there are still concerns the plant 
will become extinct in unprotected areas (Botha, Witkowski and Shackleton, 2004). There are 
efforts to cultivate W. salutaris; however, the current level of cultivation does not meet the level 
of demand (Botha et al., 2004). 
 
3.2.3. Biological Activity of W. salutaris and Drimane Sesquiterpenes 
The biological activity of W. salutaris has been documented as far back as 1904 when the 
Transvaal Agricultural Journal reported the trees to be more resistant to than any other trees in 
South Africa’s Transvaal region (Simpson, 1905). Laboratory investigations into the insect anti-
feedant properties of this plant and other members of the Canellaceae family have identified 
drimane sesquiterpenes as the compound class responsible for this biological activity (Gols, van 
Loon and Messchendorp, 1996). Members of this compound class all contain the drimane 
chemical scaffold, shown in Figure 3.1. While drimane sesquiterpenes are considered 
chemosystematic markers of the Canellaceae family, these compounds are not restricted to 
plants. Drimane sesquiterpenes can be found in fungi, the defense secretions of the marine slug 
Dendrodoris limbata and in sponges in the Dysidea genus (Zapata et al., 2009; D'Ischia, Prota 
and Sodano, 1982; Montagnac et al., 1996). 
Drimane sesquiterpenes have always been identified as the compound class responsible 
for the biological activity in every investigation of plants from the Warburgia genus. Some of 
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these prior studies into biological activities of drimane sesquiterpenes will be discussed in this 
section.  
The initial investigations of the biological activity of drimane sesquiterpenes were its 
insect anti-feedant properties. The application of two naturally occurring drimanes, polygodial 
and warburganal to the surface of leaves, resulted in the decreased feeding of Colorado potato 
beetle larvae Leptinotarsa decemlineata, on leaf discs (Messchendorp, vanLoon and Gols, 1996). 
The topical application of these two compounds on the insect's cuticle also decreased food intake 
of untreated leaf discs, indicating that besides deterrent effects, these molecules influence 
feeding behavior. Polygodial, also found in Warburgia species, has also been shown to decrease 
the transmission of the potato Y virus, even by aphids considered to be highly resistant to 
insecticides (Asakawa et al., 1988).  
The antimicrobial activities of isolated drimane compounds from Warburgia have also 
been studied. Isa Kubo and colleagues reported antifungal activity against the yeasts Candida 
albicans and Saccharomyces cerevisiae (Kubo and Taniguchi, 1988; Kubo, Fujita and Lee, 
2001). Rabe et al. (1997) reported that the aqueous extracts of W. salutaris have inhibitory 
activity against Escherichia coli while others reported that the DCM extracts of the plant did not 
inhibit growth of E. coli (Rabe and van Staden, 1997; Clarkson et al., 2007). The disparity in 
these results is likely due to the different compounds that are present in plant extract prepared 
with different solvents.  
The anti-mycobacterial activities of extracts Warburgia species have also been previously 
evaluated. The DCM extract of the bark of W. ugandensis was found to be active against the fast 
growing species M. aurum, M. fortuitum, M. phlei and M. smegmatis, with minimum inhibitory 
concentration (MIC) values ranged from 4 to 128 µg/ml (Wube et al., 2010). Another study 
investigated the activity of the crude DCM extract of bark of W. salutaris against Mtb and M. 
bovis BCG (Madikane et al., 2007). This study reported that at 100 µg/ml the crude DCM extract 
completely inhibited the growth of replicating M. bovis BCG (Clarkson et al., 2007). The  
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Figure 3.1. The chemical structures of drimane sesquiterpenes. Drimane shown here is the 
chemical skeleton characteristic of all drimane compounds, also shown is the numbering system 
used for this ring system. Polygodial is a common naturally occurring drimane. Warburganal and 
Muzigadial were isolated in this study from the active extract of W. salutaris.  
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Clarkson study also reports that at 200 µg/ml the DCM extract of the mature bark completely 
inhibits the growth of Mtb. However, neither the data nor the testing methods were published. 
Therefore conclusions cannot be drawn about the differences in the inhibition between the two 
Mycobacterium species.  
This dissertation project differs from past investigations into the inhibitory activity of W. 
salutaris. First, these past studies used the disc diffusion method to evaluate the inhibitory 
activity. This method has not proven to be the best way to make quantitative measurements of 
the MIC. Additionally, none of these studies looked at the inhibitory activity of Mtb under 
growth inhibiting conditions. 
 
3.3 Methods 
 
The steps of the plant extraction process and the bioassay-guided fractionation are 
outlined in the schematic diagram in Figure 3.2 and discussed in detail below. 
 
3.3.1. Plant Material and Plant Extraction 
The mature bark of W. salutaris was obtained from Parceval Pharmaceuticals (Ltd), 
Wellington South Africa. Small pieces of bark were ground with an industrial blender. 250 g of 
powdered plant material was extracted with 1.5 L DCM over a period of 72 hours with agitation 
at room temperature. The extract was then vacuum filtered from the remaining plant material 
(Figure 3.2). 
 
3.3.2. High Performance Liquid Chromatography Pretreatment 
 Liquid-Liquid extraction: An equal volume of hexane was added to the DCM plant 
extract. This caused colloidal particles to fall out of solution and the resulting clear, light brown 
liquid was collected. This liquid was then evaporated to dryness using a rotary evaporator.  
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Size exclusion media, Sephadex LH20, was allowed to swell for approximately 3 hours 
in acetonitrile and then poured into a Fischer glass column. The dried crude plant extract was 
dissolved in acetonitrile and applied to the column. Acetonitrile was delivered manually at room 
temperature. All eluate was pooled and rotary evaporated to dryness. 
 
3.3.3. Reverse phase flash chromatography  
Flash chromatography was performed on the product obtained from the size exclusion 
chromatography. The 55.8 mg sample was loaded onto Celite 545 with acetonitrile. The celite 
was added to the 12 g silica gel loading column (RediSep Rf Gold™). A solvent gradient of 
water progressing to 100% acetonitrile was used. Ultra violet (UV) absorption was used to 
monitor the separation of the compounds at 230 nm and 260 nm, the absorbance maxima of 
several drimane compounds (Clarkson, 2008). The fraction collector is coupled to absorbance 
detection and fractions are only collected when the absorbance levels becomes greater than the 
baseline. Portions of the sample that did not contain compounds with absorbance’s at these 
wavelengths were also collected separately and saved. 
 
 
3.3.4. High Performance Liquid Chromatography (HPLC) 
 The dried samples which resulted from the flash chromatography were dissolved in ~200 
µl of acetonitrile and injected into the HPLC (Agilent 1100 C18 column). A solvent gradient 
using water and acetonitrile (a gradient decreasing from 95% H2O to 0% H2O for 40 minutes 
followed by 10 minutes of 100% acetonitrile) with a flow rate 3.6 mL/min and a pressure of 400 
bar. A diode array detector recorded the absorbance of four wavelengths (210, 230, 260, 320 nm) 
corresponding to the ultraviolet absorbance maxima of several known drimane sesquiterpenes 
compounds (Clarkson, 2008). An initial run was used to determine the boundaries between each 
fraction with the intention to include the minimum number of peaks in each fraction. A total of 
eighteen fractions were collected over the entire preparative run. The boundaries of the 18  
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fractions were designed to include the minimum number of peaks, and therefore the minimum 
number of compounds in each fraction. 
 
3.3.5. NMR Identification of Isolated Drimanes 
HPLC fractions were dried under nitrogen gas and dissolved in deuterated chloroform 
(Cambridge Isotope Laboratories). Samples were placed in microscale NMR tubes (Shigemi 
Inc.). NMR spectra were recorded on a Varian INOVA 600 NMR (600 MHz for 1H, 151 MHz 
for 13C) using a HCN indirect-detection probe. NMR spectra were processed using Varian 
VNMR and MestreLabs MestReC software packages, with the assistance of the Cornell 
University NMR facility director Dr. Ivan Keresztes. 
 
3.3.6. Evaluating Anti-Mycobacterial Activity  
 Cultures of M. bovis BCG were grown from -80 °C frozen stocks to midlog phase in 
Middlebrook 7H9 broth (Difco Laboratories). The bacteria were grown at 37 °C in Middlebrook 
7H9 broth, supplemented with 0.2% glycerol, 0.05% Tween 80, 0.5% bovine serum albumin 
(BSA), 0.2% dextrose, and 0.085% NaCl (Larsen, Biermann and Jacobs, 2007). Experiments 
were performed using mid- to late-logphase cultures (optical density measured at 580 nm, 0.5 – 
0.8 absorbance units (AU). 
To assess bactericidal activity, the reaction wells of standard 96 well plates were prepared 
with 98 µL of 7H9 medium and 100 µL M. bovis BCG inoculum. The fractions to be tested were 
dried and dissolved in DMSO and 2 µL volumes were added to the reaction well to yield a final 
volume of 200 µL. Rifampicin (RIF) at an experimental concentration of 0.5 µg/ml and dimethyl 
sulfoxide (DMSO) were included as positive and negative controls respectively.  
 
• Growth inhibiting conditions: Midlog phase cells (A580 0.8–1.0 AU) of M. 
bovis BCG, previously grown in growth sustaining media, were prepared in 7H9 at 
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pH 5.5, 0.5 mM NaNO2 with 10% solution composed of (0.5% BSA, 0.85% NaCl), 
0.02% tyloxapol, 0.05% butyrate) (Bryk et al., 2008).  
• Growth sustaining conditions: Midlog phase cells (A580 0.8–1.0 AU) were 
prepared in 7H9 at pH 6.8. These test conditions include 20% O2, pH 6.8, and 7H9 
medium enriched with glycerol as a carbon source. (Bryk et al., 2008). 
 
After 3 days, killing was assessed either by measuring the optical density or by plating 
the cultures on solid medium. For the growth inhibiting conditions following the 3-day exposure, 
killing was assessed by dilution into growth sustaining media and outgrowth after 4 days was 
determined via optical density (Tecan SPECTRAFLUOR Plus). To plate on solid media, growth 
media was supplemented with 10% oleic acid-albumin-dextrose-catalase-enriched (OADC) and 
incubated at 37 °C. Colony forming units were counted after 14-21 days. 
 
3.3.7. Synthetic Drimane Compounds 
Synthetic drimane compounds were obtained from Dr. Duy Hua, a collaborator from the 
University of Kansas, Department of Chemistry. The structures of all 31 compounds are shown 
in Appendix A.  
 
3.3.8. Calculating IC50 
A nonlinear regression analysis was performed on the dose-response data to calculate the 
half maximal inhibitory concentration (IC50). The vehicle control DMSO and the positive control 
RIF were used to calculate normalized percent inhibition of each concentration. The percent 
inhibition vs. log concentration was plotted and GraphPad Prism software, using the method of 
least squares, determined the values of the following equation:  
 
  Percent Inhibition = Bottom + 
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In this this fitting the slope was not assumed to be one; rather the slope was determined as one of 
the fit parameters.  
 
3.4. Results and Discussion 
 
3.4.1. Fractionation of W. salutaris 
HPLC is a technique often used in natural products research to separate the individual 
components of a crude extract. Here HPLC was used to obtain fractions with simplified chemical 
compositions so that the subsequent NMR spectra could be more easily analyzed. HPLC requires 
that samples be particle free and completely soluble (Uihlein, 1988). The crude extract of W. 
salutaris, did not initially meet these requirements; it was an opaque liquid and when dried it was 
a very waxy substance. Two pretreatment steps were needed before HPLC could be preformed. 
The pretreatment steps were intended to remove substances that would damage an HPLC 
column, while minimizing loss of those compounds responsible for the biological activity. 
The first pretreatment step was a liquid extraction with hexane. The purpose was to 
remove any unfiltered solids, especially colloidal particles. Small colloidal particles were not 
easily removed from the solution with conventional filtration methods. Once hexane was added, 
the overall density of the solution was reduced so that the colloids, which were denser, settled 
out of solution and could be more easily removed. This method was employed instead of waiting 
sufficient time, perhaps several days, for coagulation and settling or using several costly filters. 
The product of this procedure was more transparent than the initial crude extract. 
The second pretreatment step performed was size exclusion chromatography using the 
adsorbent media Sephadex LH20. Size exclusion chromatography can be used as a fractionation 
step but it can also be used to remove high molecular weight and polymeric material from a 
sample (Ghisalberti, 1993; Vihma et al., 1990). The size exclusion product of the W. salutaris 
extract was transparent yellow and had improved solubility compared to the previous product of 
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hexane treatment. Unfortunately, residue was visible on the column that could not be removed 
even after several sequential washes with DCM and acetonitrile. 
The inhibitory activity of the initial DCM crude extract, the liquid extraction product and 
the size exclusion chromatography eluate, were evaluated in a dose dependent manner against 
replicating M. bovis BCG. This bacterium is a slow growing Mycobacteria that is pathogenic to 
cattle but not to humans. M. bovis BCG is considered a suitable test species because there is 
extensive genetic similarity between the two species, with only 0.01%–0.03% synonymous 
variation (Gutierrez et al., 2005).  Additionally, M. bovis BCG was used because it only requires 
a level 2 safety cabinet. Non-linear regression analysis was used to calculate concentration that is 
required for 50% inhibition in vitro (IC50). The IC50 of the DCM crude extract, the liquid 
extraction product and the size exclusion chromatography product were determined to be 6.0 
µg/mL ( ± 4.8 -7.4), 5.3 µg/mL ( ± 4.1 -7.0) and 8.0 µg/mL ( ± 7.2 -8.7)  respectively (Table 3.1, 
Figure  3.3).  
 
 
Table 3.1.  Summary of IC50 analysis of the different fractionation steps of W. salutaris 
 
 
Crude DCM  
Extract (ug/ml) 
DCM/Hexane    
Extract (ug/ml) 
Size Exclusion  
Product (ug/ml) 
Best-fit values    
IC50 6.0 5.3 8.0 
HillSlope 2.7 1.4 4.1 
95% Confidence Intervals    
IC50 4.8 to 7.4 4.1 to 7.0 7.2 to 8.7 
HillSlope 1.2 to 4.2 0.85 to 2.0 3.0 to 5.4 
Goodness of Fit    
R square 0.9778 0.9794 0.9972 
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Figure 3.3. Inhibitory activity of W. salutaris fractions. The initial crude DCM extract (☐), after 
the crude DCM extract was treated with hexane (☐), the product of the size exclusion product (☐) 
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Figure 3.4. The product of the size exclusion fraction was evaluated for activity against M. bovis 
BCG under both growth-inhibiting and growth-sustaining conditions. The dashed line represents 
50 percent inhibition based on the vehicle control. 
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The removal of colloidal particles and other insoluble materials that contributed to the 
overall weight of the extract, but not to the biological activity, should have decreased the IC50 
with each fractionation step. However, the relatively identical IC50 values of 6.0 and 5.3 indicate 
that some compounds with biological activity were also removed (Figure 3.3 and Table 3.1). The 
particles that were removed were colloidal particles or residue that remained on the column and 
it was not possible to test them for biological activity. The decision to continue with the 
bioassay-guided fractionation, despite the apparent loss of some active components, was also 
influenced by the limited access to additional plant material. Warburgia salutaris is a threatened 
species and the availability of plant material is limited and expensive. This made it impossible to 
perfect the separation procedures. It would have been ideal to isolate every compound in the 
plant that may have contributed to the activity. However, the benefits of the improved solubility 
and suitability of the sample for HPLC was thought to be more important than preventing the 
loss of some of the components of the extract. In plants there are thousands of secondary 
metabolites and that are often distributed among a few compounds classes. It is likely that any 
biologically active compounds that were lost were from the same compound class as the active 
compounds in the fraction that remained.  
 The product that resulted from the size exclusion chromatography had an IC50 of 8.0 (± 
7.2 - 8.7), which is slightly higher than the previous fractionation steps. This indicates an 
additional loss of biologically active compounds. This fraction was tested against non-replicating 
Mycobacterium and results demonstrate that the pooled eluate from the size exclusion column 
still contains inhibitory activity against M. bovis BGC in a dose dependent manner under both 
conditions (Figure 3.4).    
Flash chromatography was used to create a less complex mixture for subsequent HPLC 
separation (Ghisalberti, 1993). In flash chromatography, the precise conditions (including the 
solvent used and the gradient elution) are not standard and are typically determined for each 
sample. In this case, a step gradient of water and acetonitrile was used similar to previous 
publications of Warburgia fractionation (Clarkson, 2008). The absorbance of the eluate was 
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monitored at two UV wavelengths (230, 260 nm) that drimane compounds are known to absorb. 
Fractions were only collected when the UV absorbance was above the baseline. There were 
portions of the sample that didn’t absorb light at the wavelengths chosen. These were collected 
and saved in the event that they needed to be analyzed in the future. 
The flash chromatography spectrum showed that there was poor resolution between 
components of the extract (Figure 3.5). However, with limited sample there was not an 
opportunity to further evaluate the elution properties and optimize the experimental conditions. 
This method was only marginally effective in separating the compounds contained in the extract, 
which appeared to be of similar polarity. The flash chromatography fractions were therefore 
pooled into three samples, (Figure 3.5). HPLC was performed on the sample containing fractions 
41-49 because it was more soluble than fractions 51-56, making it easier to test biologically, and 
larger than fractions 37-39. 
HPLC separation was monitored using UV-visible spectra of four wavelengths that 
drimane compounds are known to absorb. The HPLC chromatogram showed well-defined peaks, 
according to the samples absorbance spectra at 210, 230, 260 and 320 nm, (Figure 3.6). All 
fractions were tested for biological activity at 100 µg/mL against replicating M. bovis BCG 
(Figure 3.7). The data suggests that each fraction contained some compound(s) that contributed 
to the overall biological activity of the extract.  
 
3.4.2. NMR Identification of Drimane Compounds  
The 18 dried HPLC fractions were all below half a milligram in weight. Some portion of 
each sample was used in biological testing and was therefore unrecoverable. Consequently, it 
was difficult to prepare NMR samples that had high enough concentrations for 13C spectra. 
Microscale Shigemi NMR tubes were used to reduce the needed volume of the sample from 
approximately 600 µL to about 250 µL, effectively doubling the concentration. Additionally, the 
use of the solvent DMSO in biological testing was difficult to completely remove from samples. 
The presence of trace amounts of DMSO resulted in prominent peaks in the NMR spectra that 
! 73 
obscured peaks of the sample (Gottlieb, Kotlyar and Nudelman, 1997). Two fractions could be 
prepared at a high enough concentrations (HPLC fraction 7 and 14, Figure 3.6) and 13C NMR 
spectra were obtained. 
 
 
 
 
 
 
Figure 3.5.  Flash Chromatography of the size exclusion product. The three shaded regions 
represent the pooled fractions 37-39, 41-49, and 51-56.  
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Figure 3.6. HPLC of flash chromatography fractions 41-49. The separation of the sample was 
monitored via UV wavelengths that drimane compounds are known to absorb, 210nm (☐), 
230nm (☐), 260 (☐), 320nm (☐). 18 samples were collected. Fractions 7 and 14 are shaded (☐).  
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Figure 3.7. Percent inhibition of each of the HPLC fractions against M. bovis BCG under growth 
sustaining conditions. The percentages are normalized against the positive and vehicle control 
RIF and DMSO respectively. 
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One dimensional (1D) 1H-NMR (600MHz) spectra were acquired for HPLC fraction 7, 
the sample that eluted between 41.48 to 42.48 min. The HPLC chromatogram suggests that this 
fraction contains two distinct compounds. However, there was enough information to obtain the 
structure of the most prominent compound in this sample was elucidated. The 1H-NMR spectrum 
showed signals of two aldehyde groups (δ = 9.59, doublet, J = 0.8 Hz, H-11; 9.38, singlet, H-12) 
that were further confirmed by carbonyl signals observed in the 13C-NMR spectra at 201.12 and 
192.56. Also identified were an olefinic hydrogen (δ = 7.19, d, J = 4.7, 3.2 Hz, H-7), a hydroxyl 
group (δ = 4.11, doublet, 11-OH), two methyl groups (δ = 1.02, H-14; 0.81, H-15), a methine 
resonance (δ = 2.01, d, J = 4.7 Hz, H-5), and excocyclic methylene protons (δ = 4.88 and 4.70, 
triplet, J = 1.8,18.8 Hz, H-13). The compound was identified as muzigadial, (1S, 4aS, 8a S)-1-
hydroxy-5,5,8a-trimethyl-1,4,4a,5,6,7,8,8a octahydronaphthalene-1,2-dicarbaldehyde), Figure 
3.1. This compound was previously isolated from W. salutaris and W. ugandensis. The NMR 
spectra obtained were in agreement with observed shifts in previous publications (Table 3.2, 
Appendix A) (Clarkson et al., 2007; Kioy, Gray and Waterman, 1990; Mashimbye, Maumela and 
Drewes, 1999). 
There was enough information to determine the structure of the most abundant compound 
in HPLC fraction 14 (tR = 46.18- 47.0 min).  This spectrum exhibited two aldehyde resonances (δ 
= 9.7, doublet, J = 1.5 Hz, H-11; 9.39, singlet, H-12) and a hydroxyl group (δ = 4.08, doublet, J = 
1.5 Hz, 11-OH) similar to those of muzigadial. Three methyl groups were identified at (δ = 0.92, 
H-13; δ =0.97, H-14, δ = 1.07, H-15).  The 13C NMR assignments are in agreement with those 
reported previously and by comparison of structurally related compounds, Table 3.3 (Wube et 
al., 2005; Clarkson et al., 2007). The compound was identified as warburganal, (1S)-
1,4,4aα,5,6,7,8,8a- Octahydro-1α-hydroxy- 6β, 8aβ- dimethyl-5-methylene-1,2-
naphthalenedicarbaldehyde, Figure 3.1.  
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Table 3.2. H1 and C13 NMR spectra data for warburganal (HPLC Fraction 14) 
 
Carbon No. δ, ppm Proton δ, ppm Position Splitting JHH, Hz 
C-1 31.38 1.67 ax ddd 12.8,12.5, 5.9 
  1.01 eq ddd 12.8, 5.1, 3.2 
C-2 17.75 1.47 ax m  
  1.51 eq m  
C-3 41.37 1.24 ax ddd 13.2, 12.9, 5.1 
  1.42 eq dddd 13.2,3.2, 3.2, 1.8 
C-4 32.92     
C-5* 41.54 1.87 ax dd 11.9, 5.3 
C-6* 25.92 2.32 ax ddd 20.9, 2.6 
  2.56 eq dd 20.9, 5.3, 5.3 
C-7 157.46 7.24  ddd 5.3, 2.6 
C-8 140.21     
C-9 77.55     
C-10 41.4     
C-11 202.13 9.7  d 1.5 
C-12 192.64 9.39  s  
C-13 33 0.92  s  
C-14 22.08 0.97  d 0.7 
C-15 17.02 1.07  d 0.8 
9-OH  4.08  d 1.5 
 
*J's measured in gCOSY 
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Table 3.3. H1 and C13 NMR spectra data for muzigadial (HPLC Fraction 7) 
 
 
Carbon No. δ, ppm Proton δ, ppm Position Splitting JHH, Hz 
1* 30.77 1.95 ax ddd 14, 13, 4.3 
  1 eq ddd 13, 3.3, 3.3 
21 31.53 1.07 ax dddd 13, 13, 13, 3.7 
  1.64 eq dddd 13, 3.5, 3.5, 3.5 
3 38.09 1.94 ax m  
4 151.51     
52 39.9 2.51  m  
63 27.48 2.46  m  
  2.59  m  
7 155.6 7.19  dd 4.7, 3.2 
8 139.62     
9 77.36     
10 42.12     
11 201.12 9.59  d 0.8 
12 192.56 9.38  s  
13 105.97 4.88  t 1.8 
  4.7  t 1.8 
14 18.3 1.02  d 6.6 
15 15 0.81  s  
9-OH  4.11  d 0.8 
 
 
*J's measured in gCOSY 
1Three similar couplings averaging to 3.5 
21H from gCOSY, 13C from HMBC due to overlap w/ DMSO (2.55/40.9) 
31H from gCOSY due to overlap w/ DMSO (2.55/40.9) 
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3.4.3. Biological Activity of Synthetic Drimane Compounds 
Each of the thirty-one synthetic drimane compounds (Appendix A) were tested at 50 
µg/mL. Nine compounds inhibited the growth of Mtb by more than 65%, (Compounds 4, 6, 8, 9, 
15, 18, 19, 23 and 24, Figure 3.8). The 31 synthetic compounds were tested at a single 
concentration due to limited compound availability. These structures are difficult to synthesize 
and each compound has multiple chiral centers. The discussion to follow focuses on common 
features of the natural and synthetic compounds that may contribute to biological activity (Figure 
3.8, Appendix A). The biological activity of a molecule reflects a combination of different 
physical interactions. Any comprehensive analysis would require a larger number of compounds 
than the 31 compounds available. Additionally, these compounds would have to be more similar 
in structure than the synthetic compounds tested. 
 
• Functional groups at the C9 position 
Previous publications have indicated that the unsaturated dialdehyde functionality at the 
C8- C9 position as the source of the biological activity. This is based investigations of the 
antibiotic properties, the hot taste to humans, and antifeedant activity of these compounds 
(Jansen, de Groot 2004). Tangiguchi et al. (1998) also investigated the inhibitory activity of 
naturally occurring drimane compounds against the yeast Saccharomyces cerevisiae. They 
reported that when the C9 aldehyde groups were reduced the inhibitory activity was lost 
(Tangiguchi et al., 1988). While these conclusions were not based on investigations into the anti-
mycobacterial activity, it did prompt a closer look at the functional groups that the C9 position.  
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Figure 3.8 Percent inhibition of each of the synthetic drimane compounds against M. bovis BCG 
under growth sustaining conditions. The percentages are normalized against the positive and 
vehicle control RIF and DMSO respectively. 
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The aldehyde functional group at the C9 position is largely absent from the synthetic 
drimanes tested in this study. In fact, only one of the nine synthetic compounds with inhibitory 
activity above 65% had an aldehyde at this position (Compound 23). Some of the synthetic 
compounds contained other oxygenated substituents at this position such as primary alcohols 
(Compound 6, 9, 19), secondary alcohols (Compound 4 and 8) and an ester (Compound 18) 
(Appendix A). This does suggest that the C9- aldehyde group may not be necessary for activity 
of the synthetic drimane compounds. 
It is interesting to compare the activity of compound 7 and 20, whose only structural 
difference is that compound 7 has a primary alcohol at the C9 position and compound 20 has an 
aldehyde at this position. Compound 7 demonstrated nearly 60% percent inhibition while 
compound 20 inhibited less than 20 percent of bacterial growth. Additionally, two compounds, 
15 and 24, do not contain any oxygen atoms at this location, and still showed inhibitory activity 
above 90%. Two possible inferences can be drawn; either the presence of an aldehyde group at 
the C9 position is not specifically necessary for the biological activity or the mechanism of 
action of drimane compounds in Mycobacteria differs from the proposed mechanism of drimane 
compounds in yeast.  
 
• Degree of Saturation 
The degree of saturation is important to the biological activity of the molecule; it can 
change the orientation of a molecule and affect its activity and selectivity. Many drimanes 
isolated from plants contain a saturated C7-C8 bond. This was not the case in the synthetic 
drimane compounds; only one out of the nine biologically active synthetic compounds 
(compound 9) had a double bond at this position. Compounds 6 and 9 have the same structure 
except that one member of the pair has a C7-C8 double bond. Both compound 6 and 9 were 
active with 89% and 77% inhibition, respectively.! This suggests that a double bond at this 
location is not needed for activity. 
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 Another pair of compounds that differ in saturation is compounds 22 and 23. Compound 
22 has a C7-C8 double bond with only 5.8% inhibition and compound 23 has a C8-C12 bond 
double bond with 73% inhibition. This also suggests that the presence of a double bond does not 
necessarily confer activity. 
 
• Polycyclic structures 
Many synthetic drimanes have a third or a fourth ring at C8-C9 position. For example, 
compounds 4 and 8 have lactone and compounds 13-17 have hexane ring. Compound 16, which 
has a diether ring at C3 position and 17 are not active. Compounds 25-31 all have at least two 
additional six member rings at this position. This suggests that one ring at this position does not 
affect activity, but any more ring structures at this position makes the compound too large to 
interact with its target. 
 
• Inconclusive structural attributes 
There are other structural features of the synthetic compounds are noteworthy, although 
they cannot always be used to draw concrete conclusions regarding their contribution to the 
biological activity. 
 
i. There are no substituents on C1, C2, C6, C7 (with the exceptions of compound 12 which 
has a substituent on C6). It is not clear whether the absence of a constituent is necessary 
for activity. 
ii. All compounds have a dimethyl at the C4 position except compound 12, which has 
nothing and 13, which has one methyl group. Additionally, naturally occurring drimanes 
have some variation at this carbon. For instance polygodial and warburganal have the 
dimethyl group, while muzigadial has an alkene group. There seems to be no apparent 
contribution of to the biological activity of this carbon.  
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iii. All of the synthetic compounds have a hydrogen atom in the same orientation (pointing 
out of the plane) at the C5 position, except compound 12 which has a different orientation 
and compound 13 which does not have a compound here. This data suggests that there is 
no apparent contribution of this carbon to the biological activity. 
iv. All the synthetic compounds and the naturally occurring drimanes have a methyl group at 
the C10 position, except compound 12. There is no apparent contribution of this carbon.  
 
 
 3.4.4. Selection of a Synthetic Drimane Analogue 
The results of the bioassay-guided fractionation of W. salutaris identified two drimane 
sesquiterpenes, warburganal and muzigadial, as constituents that contribute to the biological 
activity of the DCM plant extract. Access to additional plant material was limited due to the 
threatened status of W. salutaris and it was therefore necessary to find a suitable synthetic 
analogue. Synthetic compounds that are based on natural product scaffolds can present a 
challenge because these compounds are difficult to synthesize. They have multiple chiral centers 
and the synthesis can be almost a hundred steps with low yields (Jansen and de Groot, 2004). 
Therefore, without the benefit of a medicinal chemist to synthesize the most potent analogue, the 
availability of the synthetic drimane compounds had to be considered. While, compound 8 was 
not the most potent of the synthetic molecules it was structurally similar to other naturally 
occurring drimane compounds and readily available. For these reasons it was selected as a 
synthetic analogue for subsequent testing. 
Compound 8 was investigated for dose dependent activity against M. bovis BCG under 
growth sustaining and growth inhibiting conditions and was found to have an IC50 of 26.9 and 
36.2 µg/mL respectively, (Figure 3.9, Table 3.4). Based on these results, compound 8 will be 
used for subsequent investigations into the mechanism of action of drimanes in Mycobacteria. 
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Figure 3.9. Dose dependent inhibition of compound 8 against replicating M. bovis BGC (pH 
6.7), non-replicating M. bovis BCG (pH5.5, 0.5mM NaNO2) 
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Table 3.4. IC50 of Compound 8, when tested against replicating and non- replicating M. bovis 
BCG. 
 
Best-fit values Replicating Non-replicating 
IC50  (µg/mL) 26.7 36.2 
Hill Slope 1.9 3.0 
95% Confidence Intervals   
IC50 (µg/mL) 14.5 to 49.0 21.1 to 62.2 
HillSlope 0.46 to 3.3 -0.89 to 6.9 
Goodness of Fit   
R square 0.98 0.94 
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3.5 Conclusion 
 
The screening of plants used in traditional medicine has great potential in the search for 
novel anti-mycobacterial compounds. This project was able to demonstrate that the DCM extract 
of the W. salutaris was biologically active against both replicating and non-replicating Mtb. This 
project differs from other investigations into the anti-mycobacterial activity of South African 
medicinal plants in that these previous studies rarely tested for inhibitory activity against slow-
growing pathogenic species and to date no plant extracts have been screened for inhibitory 
activity against Mtb under non-replicating conditions.  
While this project was able to go further than past similar studies, it was not without its 
limitations. One challenge was the availability of plant material. Without additional plant 
material it was not possible to optimize extraction methods to ensure that no compounds that 
were contributing to the biological activity were lost during the extraction process. The relatively 
constant IC50 values between the fractionation steps suggest that some biologically active 
compounds were indeed lost. The lack of plant material also limited the number of compounds 
that could be identified from the active fraction. The structures of the two compounds, 
muzigadial and warburganal, which were present in sufficient concentrations were elucidated 
with NMR spectroscopy. This underscores the need for the sustainable use of medicinal plants 
and programs that supply plant material for scientific research.  
To facilitate future studies, the biological activity of synthetic compounds was evaluated. 
Plant-derived compounds have been used as the basis of chemical scaffolds for synthetic or 
semi-synthetic compounds. This diminishes the need for plant material and the isolation of every 
bioactive compound from plants, since the ultimate goal is to create synthetic derivatives. This 
project did not have the benefit of a medicinal chemist to synthesize derivatives of the 
compounds isolated from W. salutaris. Thirty-one synthetic compounds that were similar in 
structure were available and nine were found to inhibit growth of Mtb by more than 65%. 
Compound 8 was a biologically active synthetic compound that demonstrated inhibitory activity 
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in a dose dependent manner with an IC50 of 26.9 µg/mL and 36.2 µg/mL against replicating and 
non-replicating M. bovis BCG respectively. Compound 8 was selected to be used in subsequent 
investigations into the mechanism of action of drimane compounds in Mycobacteria. 
The experiments discussed demonstrate the potential that ethnobotanical knowledge has 
in leading the search for new chemicals with inhibitory activity against Mtb. This study also 
demonstrates that the difficulties of natural products research are unavoidable and investigations 
with natural products are resource intense multi-disciplinary endeavors. Notwithstanding, drugs 
of natural origin are essential to modern pharmacopeias and research into plant-derived 
antibiotics should continue. 
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CHAPTER 4 
Microarray Analysis of Mycobacterium tuberculosis Treated with Synthetic Drimane 
Compound 8 
 
4.1 Overview 
 
Previous chapters have described the selection and screening of South African medicinal 
plants for inhibitory activity against Mycobacterium tuberculosis (Mtb), the causal agent of the 
tuberculosis (TB). These experiments showed that the dichloromethane (DCM) extract of the 
mature bark of Warburgia salutaris demonstrated inhibitory activity against Mtb under both 
replicating and non-replicating conditions. Subsequently, the drimane class of compounds was 
confirmed as being responsible for this activity. The synthetic drimane compound 1-Hydroxy-
3a,6,6,9a-tetramethyldecahydronaphtho[2,1-b]furan-2(1H)-one (compound 8) was used here to 
investigate the intracellular target(s) of this compound class in Mtb using microarray analysis. 
Microarray analysis can be used to identify those genes that are differentially regulated in 
response to environmental stress, including an organism’s response to antibiotics. In this 
experiment, we studied the in vivo transcriptional profiles of Mtb treated with compound 8 with 
that of untreated cells. There were 125 genes upregulated more than 1.5 times untreated cells in 
Mtb exposed to compound 8 measured under growth-inhibiting conditions in macrophages. The 
subsets of genes found to be upregulated include: two transporter loci, genes in the PhoP 
regulon, genes induced after treatment with a surfactant, and genes regulated in response to low 
pH. Many of these genes represent a general stress response of the bacteria and others suggest 
that the cell wall may be the target of these compounds.  
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4.2 Introduction   
 
Attempts to eradicate TB are exacerbated by long-term persistence of non-replicating 
Mtb in macrophages of the host and the emergence of multidrug-resistant (MDR) Mtb strains 
(Onozaki and Raviglione, 2010). In the past, the primary method used to combat the 
development of resistance of bacteria to antibiotics was to modify the chemical structures of 
existing drugs (Hughes, 2003). However, this is only a short-term solution since the same 
mechanism that confers resistance to the parent molecule will eventually give rise to resistance in 
the derivative (Brazas and Hancock, 2005). What is needed are antibiotics that have new modes 
of action, and consequently an understanding of the mechanism of action is a compulsory part of 
any drug discovery effort. To demonstrate that plant-derived compounds are candidates that 
should be considered for further drug discovery research, it is important that this project go 
beyond the identification of active compounds. These microarray data can be used to provide 
insights into the cellular target of the drimane sesquiterpenes in Mtb. 
 
4.2.1 How can microarray data be used to determine the mode of action? 
Microarray analysis can be used to identify regulatory pathways and to provide the 
metabolic context of different observed responses to environmental perturbations, including drug 
treatment (Rohde, Abramovitch and Russell, 2007). When an organism is treated with a given 
compound, each compound potentially affects the expression of a distinct set of genes, often 
reflective of the primary target of that compound class, and termed the ‘gene signature’ (Brazas, 
2005). Past studies have successfully correlated the expression profile of drug-treated yeast with 
the expression profile of a yeast mutant, which then led to the identification of the target of the 
antifungal compound. Theoretically, when you compare the gene expression induced by novel 
compounds with those of compounds whose mechanism of action is more understood, you can 
validate or identify the mechanism of novel inhibitors.  
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This rather straightforward approach used in yeast studies is not as easily applicable to 
Mtb. In Mtb, microarrays were first reported to describe those genes induced after Mtb was 
treated with isoniazid (INH) treatment. The genes identified encoded proteins related to the mode 
of action. Interestingly this study also identified other genes, including those that were involved 
in the mycobacterial response to the toxicity of the INH such as efflux proteins (Wadell et al., 
2004). The microarray data obtained from Mtb studies reflect a complex host-pathogen 
interaction and this makes interpreting the microarray data challenging. Thus far in Mtb, 
microarray profiling after exposure to drugs has enabled compounds to be classified into similar 
groups based on mode of action. Complete elucidation of the mechanism of action would require 
complimentary biochemical and genetic studies, thus microarrays are generally most useful as 
hypothesis generating tools. (Wadell et al., 2004).  
Another challenge in interpreting the transcriptional response to a compound is that the 
microarray data will also include expression changes in genes that may have no relationship, 
direct or otherwise, to the mode of action of the antibiotic. There are those genes that are 
indirectly affected by inhibition of the primary target. These often represent genes mediating the 
response of the antibiotic those genes that are involved in general stress responses. Secondly, 
expression data may include genes that modulate bacterial metabolism by altering transcription 
patterns. Studies have shown that antibiotics with different chemical structures and different 
modes of inhibitory action activate or repress a wide variety of promoters in Escherichia coli and 
Pseudomonas. While these examples are not Mtb, it does suggest that antibiotics have additional 
roles other than inhibition of growth by the inhibitors of specific target functions. There are also 
genes that are differentially regulated in response to the downstream consequences of target 
inhibition. These kinds of genes are included in the expression profiles are complicating 
components in understanding microarray data. 
Comparing microarray data with previously published experiments is not conclusive. 
However, this method can be used to provide important information that will eventually lead to 
elucidating the mode of action of drimane compounds against Mtb. When the results of our 
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experiment were compared to a compendium of existing data, several subsets of genes were 
shown to be upregulated in common. These data include in vitro models of infection where 
responses to individual stimuli can be more controlled as well as expression studies in well-
characterized mutants. There was no measured effort to ignore those genes that were down 
regulated. However in focusing on previously reported studies, only upregulated genes were 
highlighted. It is also important to note that while two different time points were tested, there 
wasn’t enough information to make a time dependent analysis, nor was there sufficient statistical 
resolution to draw any conclusions about these temporal changes in expression.  
 
4.2.2 Previous studies of the mode of action of Drimanes. 
The drimane sesquiterpenes compound class was originally identified for their insect 
antifeedant properties (Kubo and Taniguchi, 1976). Drimane sesquiterpenes were later found to 
have potent antifungal activity especially against the yeast Saccharomyces cerevisiae and 
Candida albicans (Taniguchi et al., 1988). These studies prompted investigations into the 
cellular target of drimane sesquiterpenes, in particular polygodial, in yeast.  Polygodial is a 
drimane sesquiterepene structurally similar to compound 8 used in our microarray study (see 
figure 4.1). Electron micrographs showed that when S. cerevisiae cells were treated with 50 
µg/ml of polygodial, the cell membrane was fragmented and the nuclear membranes also were 
more irregular in appearance (Kubo, Fujita and Lee, 2001). A separate study by Forsby et al. 
(1992) showed that when human neuroblastoma cells were treated with low concentrations of 
polygodial, there was leakage of cellular constituents. The conclusion of these studies is that 
polygodial acts as a surfactant that nonspecifically disrupts the lipid-protein interface in 
membranes (Kubo et al., 2005).  
Previous chapters have discussed the anti-mycobacterial properties of drimane 
compounds isolated from W. salutaris. Warburgia salutaris is a popular South African medicinal 
plant and previous studies have investigated its anti-mycobacterial properties. One investigation 
into the cellular target used transmission electron microscopy to show the affect of a W. salutaris 
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extract on the cellular morphology of M. bovis bacillus Calmette-Guérin (BCG). The results 
showed that M. bovis BCG when treated with a crude extract of W. salutaris  (50 µg/mL) had an 
altered cell wall structure (Madikane et al., 2007). The mode of action of drimane compounds 
against Mtb has not been investigated using microarrays.  
 
 
 
 
 
 
 
 
 
  
 
Figure 4.1. The chemical structures of drimane sesquiterpenes. Drimane shown 
here is the chemical skeleton characteristic of all drimane compounds, also shown 
is the numbering system used for this ring system. Polygodial is a common 
naturally occurring drimane. !
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4.2.3 The Mycobacterium Cell wall 
A short discussion of the cell wall of Mtb is prudent since many of the genes upregulated 
in this study are associated with some aspect of the cell wall. The cell wall is one of three 
components of the cell envelope, which also includes the plasma membrane and a capsule 
(Figure 4.2). The Mycobacterium cell wall lies adjacent to the plasma membrane and includes a 
covalently linked layered core comprised of (moving out from the plasma membrane) 
peptidoglycan, galactofuran, highly branched arabinofuran, and finally mycolic acids (Figure 
4.2; Brennan, 2003) The low permeability of the mycobacterium cell envelope is attributed to the 
properties of the cell wall. In experiments where cell envelopes were disrupted with various 
solvents, the outer most layer, also call the capsule, consisting of free lipids and proteins are 
solubilized. However, the mycolic acid–arabinogalactan–peptidoglycan complex remains an 
insoluble residue (Brennan, 2003).  
  
Figure 4.2 A schematic of the mycobacterial cell envelope, adapted from Ouellet 
Johnston, and de Montellano, 2010. !
! 97 
4.3 Methods 
 
4.3.1 Bacterial strains and cells 
Microarray experiments were performed by Dr. Robert Abramovitch at the College of 
Veterinary Medicine, Cornell University according to a previously described procedure (Rohde 
et al., 2007). In order to increase the genetic diversity of Mtb genes in this study, two strains of 
Mtb, CDC1551 a recent clinical isolate, and H37Rv, the wild type Mtb strain, were used. Both 
were routinely cultured in 7H9-OADC medium without shaking in 75 cm2 vented tissue culture 
flasks. Bone marrow-derived macrophages were isolated from C57BL/6 mice and grown in 
Dulbecco's Modified Eagle Medium DMEM media (Rohde et al., 2007). 
 
4.3.2 Macrophage Infections and RNA Isolation 
Prior to infections, Mtb were declumped by repeated passages through a 21-gauge needle 
and resuspended in infection buffer DMEM with 5% fetal calf serum, 10mM HEPES, pH 7.4). 
Macrophage infections were initiated by centrifugation (1000xg, 10 min) of bacteria onto 
confluent macrophage monolayers followed by incubation at 37° C. Macrophages infected with 
Mtb were treated with compound 8 dissolved in minimal DMSO at a final concentration of 100 
µg /mL for either 4 or 24 hrs. The experimental control was bacteria treated only with DMSO. 
Addition of a lysis buffer (4M guanidine thiocyanate, 0.5% Na N-lauryl sarcosine, 25 mM 
sodium citrate, and 0.1M β-mercaptoethanol) selectively lysed the macrophages, leaving Mtb 
cells intact while at the same time stopping Mtb transcription and RNA degradation (Butcher et 
al., 1998; Mangan et al., 2002). Samples were vortexed and passed repeatedly through a 21-
gauge needle to separate clumps of macrophages and reduce viscosity. Intracellular Mtb were 
recovered by centrifugation at 3500 rpm for 30 minutes. Three technical replicates were 
completed. 
 
  
! 98 
4.3.3 Linear Application of Mycobacteria RNA 
Pelleted Mtb were digested with 5 µg/ml lysozyme before being lysed in Trizol at 65o C 
using a BeadBeater and 0.1mm silicon beads. Total RNA was isolated from Trizol lysates by 
chloroform extraction followed by addition of ethanol and direct application to Qiagen RNeasy 
column purification. Residual DNA contamination was removed using Turbo DNAfree DNase 
(Ambion).  
 
4.3.4 Microarray Fabrication 
Oligonucleotide microarrays consisted of 4295 open reading frames (ORF), representing 
3924 ORFs from Mtb strain H37Rv and 371 ORFs from CDC1551. Oligos were spotted in 
duplicate on Corning UltraGAP (amino-silane coated) slides (Rohde et al., 2007). 
 
4.3.5 Microarray Hybridization  
Total RNA was reverse transcribed, using indirect labeling (to ensure that probe 
populations were labeled with equivalent efficiencies), into amino-allyl cDNA using Superscript 
III (Invitrogen Life Technologies), 5’-amine modified random hexamers (Integrated DNA 
Technologies) (Xiang et al., 2002), and amino-allyl (aa) d- UTP (Sigma). CyDye fluors were 
conjugated to aa-cDNA using CyDye Post-Labelling Reactive Dye reagents (Amersham) 
containing N-hydroxysuccinimide ester derivatives of Cy3 and Cy5. After quenching the 
labeling reactions with 4 M hydroxylamine, excess reactive dyes were removed by QiaQuick 
purification (Qiagen).  
5-10 µg of Cy-labeled cDNA from paired samples (treated and untreated cells) was dried 
using a Speedvac and resuspended in 50 µl of hybridization buffer (5X Saline-sodium citrate 
(SSC) 25% formamide, 0.1% SDS, and 25 µg salmon sperm DNA). Samples were denatured at 
95o C for 5 min and briefly cooled to 60o C before being applied to arrays under a glass LifterSlip 
(Erie Scientific). Slides were prehybridized for 1 hr in 25% formamide, 5X SSC, 0.1% SDS, 1% 
BSA and washed with H2O and isopropanol. Labeled targets were hybridized to microarrays in 
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humidified slide chambers (Corning) at 45o C for 16-18 hr. Arrays were washed sequentially 
with buffer 1 (2X SSC, 0.1% SDS) pre-warmed to 45o C, buffer 2 (0.2X SSC, 0.1% SDS), buffer 
3 (0.2X SSC), and buffer 4 (0.05X SSC). Finally, slides were dipped in deionized ultra-filtered 
water before being dried by centrifugation. 
 
4.3.6 Microarray Data Analysis 
Microarrays were scanned with a GenePix 4000B (Axon Instruments, Inc.) with image 
analysis, spot intensity determination, background measurements and spot quality assessment 
conducted using Imagene software (version 6.0, Biodiscovery). Spots with signal intensities 
fewer than three standard deviations above background were excluded from further analysis. 
Subsequent normalization, statistical analysis, and visualization of array data were performed 
with Genespring 7.3 (Agilent). Genes with significant changes in expression levels relative to 
controls were identified based on fold change (1.5-fold). 
 
4.4 Results  
 
In the Mtb treated with compound 8, 125 genes were upregulated more than 1.5 times 
compared to the expression of untreated cells after both 4 and 24 hours, (see Appendix B for full 
gene list). These genes are a subset of a total of 4295 open reading frames that were examined 
and 3528 (82%) that were expressed above statistical background.  
 
4.4.1 Genes regulated by the PhoP regulon are induced  
Bacteria use surface exposed signal transduction systems as a mechanism to monitor and 
adapt to changing environmental conditions. PhoPR is a two-component signal transduction 
system, containing an environmentally responsive histidine kinase, PhoR, and a response 
regulator, PhoP, which mediate cellular responses through differential expression of genes 
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(Ryndak, Wang and Smith, 2008; Mascher, Helmann and Unden, 2006). In this microarray study 
many genes regulated by PhoP where upregulated after treatment by drimane compound 8. 
The Phop gene was identified as differentially expressed between the avirvulent Mtb 
H37Ra strain and the virulent H37Rv strain (Ryndak et al., 2008). PhoP has been shown to 
regulate the expression of genes essential for survival inside macrophages and also genes that are 
involved in lipid metabolism (Ryndak et al., 2008). The ability to survive under the variety of 
growth conditions experienced in the macrophages is one of the factors of virulence. Walters et 
al. (2006) compared the gene expression in Mtb strain H37Rv with gene expression in the phoP 
mutant and showed that 44 genes had a higher expression in the virulent wild type strain 
compared to the phoP mutant. More than half of the 44 genes identified in the Walters et al. 
study are annotated to encode proteins involved in lipid metabolism, lipid secretion and synthesis 
of components of the cell envelope. It was also found that the phoP mutant has a structurally 
altered cell envelope; complex lipids that are normally present in wild type are absent in the 
mutant (Walters et al., 2006). In our investigation 21 of the 44 genes regulated by PhoP were 
upregulated more than 1.5 fold in Mtb exposed to compound 8 as compared to untreated cells 
(Figure 4.3).  
While the function of the majority of the genes regulated by Phop is unknown, others are 
annotated to be involved in polyketide synthesis, such as pks2, pks3 and pap1. The 
mycobacterial cell wall contains a number of polyketide-derived complex lipids (Mohanty, 
Sankaranarayanan and Gokhale, 2011). It is known that pks2 and msl3 encode proteins 
responsible for the biosynthesis of sulphatides and acyltrehaloses, respectively (Gonzalo Asensio 
et al., 2006). These cell wall components are unique to pathogenic Mycobacteria. Both the pks2 
and msl3 genes were up regulated in Mtb exposed to compound 8, as compared to untreated 
cells.  
Other genes regulated by Phop are annotated to encode proteins that are localized to the 
cell envelope, including Mmpl1, Mmpl3, Mmpl8, Rv2576, Rv2373. The mycobacterium 
membrane protein large (Mmpl) family of proteins are proposed to be involved in the transport 
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of lipids and other components of the cell wall (Domenech, Reed and Barry, 2005) and will be 
discussed in Section 4.4.4. Since the upregulation of Phop is a key to survival while exposed to 
the many stress conditions in vivo, it would suggest that the increased upregulation of these 
genes in Mtb exposed to compound 8 as compared to untreated cells indicated that these bacteria 
are responding to and additional stress. These genes are not necessarily indicative of a particular 
mode of action.  
 The microbial cell wall acts as the interface between the infecting bacilli and the host 
environment therefore it is not surprising to find genes involved in the synthesis and 
modification of cell wall associated fatty acids upregulated in vivo. It is not clear whether these 
lipid moieties are part of a response to strengthen the lipid-rich mycobacterial cell wall or play a 
different role in the response of the pathogen to stress (Wadell and Butcher, 2011). The 
utilization of fatty acids appears to be common to all infection models and therefore may 
represent a fundamental adaptation to intracellular growth  (Wadell et al., 2007). 
 
4.4.2 PE/PPE Protein Family 
Our microarray data indicate that ten genes upregulated by Mtb exposed to compound 8 
are identified as belonging to the PE and PPE family of proteins (see Appendix B). These genes 
are named for their highly conserved residues near the start of their encoded proteins. The PE 
(proline-glutamate) and PPE (proline-proline glutamate) gene families represent almost 200 
genes, which is 10% of the coding capacity of the Mtb genome (Cole et al., 1998, Sampson, 
2011). Many researchers have interpreted this large percentage to be indicative of the importance 
of these genes in the pathogenesis of Mtb, and many of these genes are duplicated (Cole et al., 
1998). Originally, it was suggested that the purpose of this gene family was to promote antigenic 
diversity (Okkels et al., 2003). However, since these genes are unique to Mycobacterium, and 
they are only present in the pathogenic species of the genus, it is believed that these genes also 
play an essential role in virulence (Mukhopadhyay and Balaji, 2011). Additionally, the 
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inactivation of two PE genes resulted in decrease survival of Mtb in granulomas (Ramakrishnan, 
Federspiel and Falkow, 2000).  
 
 
 
Figure 4.3 Expression ratio of Phop regulated genes, as identified by Walters et al. (2006), Mtb 
treated with drimane compound 8 versus untreated cells.!
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Table 4.1 Genes that where identified as regulated by PhoP according to the Walters et al. 
(2006) study and their expression in Mtb exposed to drimane compound 8 vs. expression in a 
DMSO control. 
Systematic 24h 4h Description 
pks2 (Rv3825c) 3.884 2.884 Probable polyketide synthase 
pks3 (Rv1180) 3.844 1.863 Probable polyketide synthase beta-ketoacyl synthase domain, 
Rv1184c 3.406 1.893 Hypothetical proteins 
Rv3767c 3.118 1.534 Unknown 
papa3 (Rv1182) 3.009 2.423 Hypothetical proteins 
papa1 (Rv3824c) 2.863 2.115 
Probable polyketide synthase associated protein, sulpholipid 
biosynthesis 
Rv3615c 2.823 1.682 Unknown 
Lipf (Rv3487c) 2.616 1.222 Unknown  
mez Rv2332 2.566 1.323 Catalyzes the oxidative decarboxylation of malate into pyruvate 
Rv2331 2.560 1.289 Unknown 
fadd21 (Rv1185c) 2.513 1.776 Probable acyl-coAsynthase 
rv1179c 2.445 1.102 Unknown 
mmpl10 (Rv1183) 2.318 1.371 Probable transmembrane protein 
mmpl8 (Rv3823c) 2.082 1.358 Probable conserved integral membrane transport protein 
Rv2633c 1.795 1.323 Function unknown, hypothetical protein 
Rv1639c 1.518 1.074 Function unknown, probable hypothetical membrane protein 
uvra (Rv1638) 1.501 1.268 Involved in nucleotide excision repair 
Rv2396 1.938 0.823 Member of PE family, PGRS subfamily of proteins 
Rv3479 1.725 0.840 Unknown 
Rv3613c 1.490 0.781 Unknown 
nark1 (Rv2329c) 1.485 0.745 Probable nitrite extrusion protein 
Rv2376c 1.479 1.007 Unknown, predicted outer membrane protein  
Rv2632c 1.467 1.290 Function unknown, hypothetical protein 
cdh (Rv2289) 1.449 1.008 Involved in phospholipid biosynthesis 
leud (Rv2987c) 1.402 0.657 Involved in leucine biosynthesis at the second step 
Rv3477 1.398 0.627 Member of  PE family of proteins 
Rv3616c 1.379 1.100 Unknown 
rfe (Rv1302) 1.334 1.098 Involved in AG biosynthesis 
Rv0116c 1.312 1.232 Unknown  
Rv3614c 1.273 0.875 Unknown 
Rv3686c 1.172 0.810 Unknown 
Rv3478 1.160 1.123 Member of PPE family of proteins 
Rv1361c 1.142 0.926 Member of the PPE family of proteins 
Rv3312c 1.096 0.935 Unknown 
mmpl3 (Rv0206c) 1.094 0.665 Possible membrane transport protein  
fadd9 (Rv2590) 0.764 0.587 Involved in lipid degradation, probable fatty acid Co-A ligase 
MT3135 0.652 0.866 Hypothetical protein 
Rv2576c 0.556 0.857 Unknown 
fbpa (Rv3804c) 0.395 0.895 32 kDa antigen protein 85-A precursor, mycolyltransferase 
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The PE/PPE genes are notable in response to drimane compounds because a recent 
review indicates that their products are localized to the cell wall (Sampson, 2011). Cell 
fractionation and immunoelectron microscopy studies similarly concluded that all PE proteins 
contain a functional domain responsible for localization to the mycobacterial cell wall 
(Cascioferro et al., 2007). Additionally, genes belonging to the PE-PGRS (polymorphic GC-rich 
sequence) subfamily have been shown to specifically localize to the cell wall of Mtb (Sani et al., 
2010). These genes have not been shown to be involved in the general stress response of Mtb. 
However, since the function of these genes is not clear, it is premature to suggest that the 
upregulation of these may indicate that the cellular target of these drimane compounds is the cell 
envelope. 
 
4.4.3 Genes that respond to the surfactant SDS 
Manganelli et al. (2001) used microarrays to compare the gene expression profiles of the 
wild type Mtb strain H37Rv after exposure to sodium dodecyl sulfate (SDS), an anionic 
detergent commonly used to denature proteins and disrupt membranes (Tan et al., 2002). A total 
of 62 genes were upregulated in wild type Mtb H37Rv after exposure to SDS as compared to 
untreated cells. In our study 20 of the 62 genes identified as being SDS-sensitive were 
upregulated by more than 1.5 times after both 4 hours and 24 hours of exposure to drimane 
compound 8 as compared to untreated cells (Figure 4.4). 
Many of the genes up regulated after exposure to SDS were found to be involved in fatty 
acid degradation. In the macrophage, Mtb switches to the utilization of lipids and fatty acids as 
alternate carbon sources (McKinney et al., 2000). One gene central to fatty acid metabolism and 
found to be upregulated here is aceA, which encodes for the enzyme isocitrate lyase (Icl), an 
enzyme essential for the metabolism of fatty acids. Icl is the first enzyme in the glyoxylate cycle, 
and is upregulated in non-replicating of Mtb. It has also been observed that an icl1 null strain of 
Mtb was not able to sustain the chronic, persistent infection seen in mice infected with wild-type 
Mtb (McKinney et al., 2000). Moreover, bacteria lacking both icl1 and icl2 are unable to grow 
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on fatty acids or in macrophages, and are rapidly cleared from the lungs of infected mice 
(Muñoz-Elías et al., 2005). These observations suggest that adaptation to the host environment 
involves a metabolic shift in the carbon source used by the bacteria to the acetyl-CoA generated 
by the b-oxidation of fatty acids (Gould et al., 2006). 
Much of this work on the upregulation of genes associated with fatty acid metabolism 
focuses on changes in the metabolic pathways required for survival within the activated 
macrophages of the host. Mtb preferentially utilizes fatty acids and this preference is thought to 
be due to the increased availability of lipids (Mckinney et al., 2000). However, there is growing 
evidence that indicate this metabolic change is a part are part of innate programming in response 
to persistence, not the carbon source. In Mtb exposed to stress conditions that prevent replication 
and in media that contained different carbon sources, the switch of carbon metabolism from 
sugars to fatty acids was independent of the carbon source or the stress response (Shi et al., 
2010). This would suggest that the upregulation of these genes may be a response of the bacteria 
to the stress induced by compound 8. 
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Figure 4.4 Managanelli (2001) identified genes in Mtb differentially expressed 
after exposure to SDS. The expression of these genes were investigated in Mtb 
exposed to drimane compound 8. This figure shows the expression ratio of SDS 
regulated genes in Mtb treated with drimane compound 8 compared to untreated 
cells. !
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Table 4.2 The expression ratio of genes differentially regulated in response to exposure with 
SDS.  
 
Systematic 24h 4h Description 
35kd_Ag 
(Rv2744c) 1.674 1.813 Unknown 
Acea (Rv0467) 2.351 1.574 
Probable isocitrate lyase, involved in glyoxylate 
bypass 
Atsa (Rv0711) 2.684 1.798 
Arylsulfatase, involved in the mineralization of 
sulfates  
Hsp (Rv0251c) 2.405 1.763 
Possibly heat shock protein belonging to HSP20 
family 
Htpx (Rv0563) 2.379 1.906 
Probable heat shock protein X, likely 
transmembrane) 
Iles (Rv1536) 2.017 1.104 Involved in the catalytic activity of isoleucine 
Mmpl5 (Rv0676c) 3.157 2.951 
Probable transmembrane protein involved in fatty 
acid transport  
Mmps5 (Rv0677c) 3.855 3.970 Possible membrane protein  
Rv0146 2.080 1.526 
Possible methyltransferase involved in lipid 
metabolism 
Rv0465c 2.541 1.593 Possible transcriptional regulator 
Rv0678 3.667 5.241 Unknown 
Rv0981 1.731 2.390 
Transcriptional regulatory protein of a two 
component system 
Rv0997 2.140 2.196 Unknown 
Rv1057 2.913 2.774 Unknown  
Rv1168c 1.586 0.905 Member of the PPE-family of proteins 
Rv1169c 1.836 0.977 Member of the PE family of proteins  
Rv1806 4.450 2.036 Member of the PE family of proteins 
Rv1807 2.427 1.560 Member of the PE family of proteins 
Rv1808 3.024 1.698 Member of PPE family of proteins 
Rv1809 3.201 1.749 Member of PPE family of proteins 
Rv2050 2.142 1.904 Unknown 
Rv2745c 1.664 1.847 Possible transcriptional regulatory protein 
Rv3406 2.256 2.241 Unknown 
Cysd (Rv1285) 0.884 0.833 Probable sulfate adenylate transferase subunit 2 
Cysn (Rv1286) 0.807 0.843 Probable sulfate adenylate transferase, 
Ding (Rv1329c) 1.334 1.024 Probable ATP-dependent helicase 
Fada (Rv0859) 1.048 0.751 
Function unknown, probable involvement in lipid 
metabolism 
Fadb (Rv0860) 1.267 0.857 Involved in fatty acid degradation 
Fadb2 (Rv0468) 1.091 1.378 Probable 3-hydroxyacyl-coa dehydrogenase 
Fadd9 (Rv2590) 0.764 0.587 
Involved in lipid degradation, probable Acyl-
CoA synthetase 
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Table 4.2 Continued 
  
  
Systematic 24h 4h Description 
Fade23 (Rv3140) 1.131 1.510 
Involved in lipid degradation, putative acyl-CoA 
dehydrogenase  
Fade24 (Rv3139) 0.955 1.645 Probable acyl-CoA dehydrogenase 
Glta1 (Rv1131) 0.901 1.058 Probable citrate synthase 
Nada (Rv1594) 1.115 1.204 Quinolinate synthetase. 
Nadb (Rv1595) 0.923 1.252 Probable L-aspartate oxidase 
Nadc (Rv1596) 0.361 2.022 
Involved in de novo biosynthesis of NAD and 
NADP 
Rv0516c 0.996 0.974 May be involved in regulating sigma factor 
Rv0712 1.069 1.503 Unknown 
Rv0789c 0.901 1.239 Unknown 
Rv1129c 0.878 0.774 Unknown 
Rv1130 0.786 1.181 Involved in methyl citrate cycle 
Rv1195 0.898 0.920 Member of the PE family of proteins 
Rv1196 1.087 0.883 Member of PPE family of proteins 
Rv1199c 1.194 1.288 
Possibly required for the transportation of 
insertion elements 
Rv2053c 1.409 1.432 Probable transmembrane protein  
Rv2743c 1.201 1.413 Unknown 
Rv3023c 0.811 1.072 Probable transposase 
Rv3115 0.569 0.772  Probable transposase 
Rv3854c 0.650 1.153 Possible monooxygenase 
Rv3855 0.520 0.970 Possible transcriptional regulatory protein 
Sige (Rv1221) 1.153 1.285 
Alternative sigma factor of extracytoplasmic 
function (ECF) family 
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4.4.4 Efflux systems 
  The genes associated with two efflux pumps were upregulated in Mtb exposed to 
compound 8. Both eukaryotic and prokaryotic organisms have efflux pumps that remove 
molecules from within the cell (De Rossi, Ainsa and Riccardi, 2006). Many of these efflux 
systems have broad substrate profiles that allow structurally diverse compounds to be exported 
from the cell, including antibiotics of different chemical classes (Ryan et al., 2001). Efflux 
systems have been identified as a resistance mechanism in many bacteria, including Mtb, to 
antibiotics. It is believed that each transporter originally evolved to transport a physiological 
substrate or group of related substrates and the ability of these transporters to efflux toxins is 
merely an opportunistic side effect (De Rossi et al., 2006). The ability of these proteins to 
extrude antibiotics and other toxins from the cell is likely a serendipitous result of the ability of 
these pumps to transport a wide range of substrates (Piddock, 2006). It is believed that genes 
encoding efflux pumps are not specific to a given antibiotic and the upregulation is believed to 
be a response to environmental stress (Brazas and Hancock, 2005). 
 
• The efflux system encoded by mmpS5-mmpL5  
The genes MmpS5, MmpL5 and Rv0678 were found to be upregulated by Mtb exposed to 
compound 8 by more than 2 fold (Figure 4.5). The MmpL5 (mycobacterium membrane protein 
large) and MmpS5 (mycobacterium membrane protein small) have been previously identified to 
encode a hypothetical efflux system belonging to the resistance nodulation division (RND) 
family of transporters. The gene Rv0678 has been linked to the transcriptional regulation of these 
two transporter genes (Milano et al., 2009).  
Pairwise alignment of amino acid residues of MmpL5 in Mtb and Escherichia coli AcrA 
have shown the two proteins to be analogous (De Rossi et al., 2006). Sequence similarity was 
also found between the E. coli gene AcrB and mmpS5, although to a lesser extent. To date, no 
analogous gene analogous to TolC has been identified in Mtb. The E. coli AcrAB-TolC is the 
typical example of the RND family tripartite system of transporters. This system includes 1) a 
! 110 
transporter (efflux) protein located in the inner membrane named AcrB, 2) an accessory protein 
located in the periplasmic space named AcrA and 3) an outer membrane protein, TolC (De Rossi 
et al., 2006). 
The Mmps5-MmpL5 efflux pumps were originally identified in the resistance mechanism 
of Mtb to antibiotics belonging to the azole compound class (Milano et al., 2009). While the 
exact natural substrates of the mmps5-mmpl5 efflux pump remain unidentified, it has been 
suggested that these proteins are involved in the transport of fatty acids because they are flanked 
by genes involved in lipid metabolism and polyketide biosynthesis (Milano et al., 2009; Butcher, 
Mangan and Monahan, 1998).  
 
• Genes Encoding the Putative Tetronasin ABC transporter 
ATP-binding cassette (ABC) transporters represent a super family of multi-subunit 
permeases that transport molecules across biological membranes (Braibant, Gilot and Content, 
2000). These transporters contain four domains; two hydrophobic membrane-spanning domains 
and two cytoplasmic nucleotide binding domains (Davidson et al., 2008). The Mtb gene 
Rv1218c shows sequence similarity to TnrB, an ABC transporter found in Streptomyces 
longisporoflavus. TnrB is known to confer resistance to the antibiotic tetronasin (Demetriadou et 
al., 1985). Studies by Linton et al. (1994) concluded that TrnB protects the cell from tetronasin 
by removing the antibiotic from the cell. 
  In Mtb treated with compound 8, Rv1218c and the genes Rv1216c, Rv1217c and 
Rv1219c, which encode the other domains of this ABC-transporter, were upregulated in Mtb 
exposed to compound 8 (Figure 4.6). The natural substrate of this transporter is not known and 
studies suggest that this transporter is involved in mediating the efflux of a wide variety of 
chemical classes (Balganesh et al., 2010). There is not enough evidence to speculate on the role 
of this transporter. The upregulation of these genes could be the bacteria’s attempt to remove the 
drimane compounds from the cell or an increased need to transport a different substrate. 
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Figure 4.5. Expression ratio of genes MmpL5, MmpS5, Rv0678, in Mtb treated 
with compound 8 versus untreated cells after 4 and 24 hours. !
! 112 
 
  
 
 
 
  
  
Figure 4.6 Expression ratio of genes Rv1216c, Rv1217c, Rv1218c, Rv1219c, in 
Mtb treated with compound 8 versus untreated Mtb, after both 4 and 24 hours. !
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4.4.5 Mtb Genes that respond to acidification are induced. 
 
Two studies have investigated the transcriptional response of Mtb to an acidic 
environment, an important characteristic of the macrophage host. First, Yates et al. (2005) 
investigated the global transcription response of Mtb in macrophages treated with concanamycin 
A (CcA), which prevents the macrophage from acidifying as compared to Mtb in untreated 
macrophages. The Yates et al. study concluded that 44 genes were differentially regulated in 
response to an acidic pH in the macrophages. A separate study by Rodhe et al. (2007) 
investigated genes up regulated in response to an acidic pH in vitro. There are 16 genes that were 
identified in both the Yates et al. and Rodhe et al. studies as being responsive to an acidic 
environment.  
Thirteen of these the genes identified as acid sensitive were upregulated more than 1.5 
times in the Mtb treated by drimane compound 8 (Figure 4.7). The Rohde et al. study concluded 
that pH might serve as an environmental cue that the bacteria uses to initiate metabolic changes 
and enter a non-replicating state. Many of the 16 genes have been previously discussed in 
previous sections and are upregulated in response to other stress conditions. This supports the 
idea that these genes may not be responding directly to a decrease in pH, instead are upregulated 
in response to general stress conditions. 
A gene known to be upregulated in response to a low pH is WhiB3. WhiB3 is one of 
seven Mtb whiB-like genes that encode small proteins postulated to be transcriptional regulators 
(Geiman et al., 2006). Specifically, WhiB3 binds to the principal sigma factor, RpoV, and is 
thought to play a role in bacterial survival and tissue pathology late in infection (Steyn et al., 
2002). WhiB3 and many of the whiB-like genes are upregulated in response to a wide range of 
stressful stimuli. Some of these stimuli are encountered in the macrophages including oxidants, 
low pH and others stess stimuli such as sodium dodecyl sulfate, and heat shock are not (Rohde et 
al., 2007). This lends to the conclusion that these genes may be induced as a part of a general 
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stress response and the upregulation of these genes in Mtb treated with compound 8 as compared 
to the untreated cells is indicative of the additional stress these cells are experiencing.  
 
 
 
 
Figure 4.7. There are 16 genes that were identified in studies by both Yates et al. (2005) and 
Rodhe et al. (2007) as being responsive to an acidic environment. This figure shows the 
expression ratio of these pH sensitive genes in Mtb exposed to compound 8 versus untreated 
cells after 24hrs. 
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Table 4.3 The expression ratio of pH sensitive genes, both Yates et al. (2005) and Rodhe et al. 
(2007),  in Mtb exposed to compound 8 versus untreated cells after both 4 and 24 hours. 
 
Systematic 24h 4h Description 
Rv2632c 1.467 1.290 Unknown 
Rv2633c 1.795 1.323 Unknown 
Rv2628 0.548 1.440 Unknown 
Rv2396 1.938 0.823 Member of PE family, PGRS subfamily of proteins 
Rv2390c 1.995 1.183 Unknown 
Rv2389c 1.267 0.819 Known to promote the growth of non growing cells 
Pks2, (Rv3825c) 3.884 2.884 Probable polyketide synthase 
Papa1 
(Rv3824c) 2.863 2.115 Involved in sulpholipid biosynthesis 
Rv3746c 1.626 1.232 Belonging to the PE family of proteins 
Mt3223 0.744 0.458 Unknown 
Rv3613c 1.490 0.781 Unknown 
Whib3 (Rv3416) 2.096 1.671 Transcriptional regulatory protein 
Lipf (Rv3487c) 2.616 1.222 Unknown 
Rv1807 2.427 1.560 Member of the PE family of proteins 
Rv1806 4.450 2.036 Member of the PE family of proteins 
Rv2030c 0.657 0.943 Unknown 
Fdxa (Rv2007c) 0.420 1.102 
Involved in electron transfer during the production of 
ferredoxin 
Pks4 (Rv1181) 2.797 1.495 Proposed to be involved in polyketide synthase 
Pks3 (Rv1180) 3.844 1.863 Proposed to be involved in polyketide synthase 
Papa3 (Rv1182) 3.009 2.423 hypothetical protein 
Rv1403c 2.556 1.980 Unknown 
Rv2627c 0.426 1.065 Unknown 
Rv2626c 0.484 1.101 Unknown 
Hspx (Rv2031c) 0.916 1.289 Belongs to the small heat shock protein family 
Rv3130c 0.646 1.208 Involved in the synthesis of triacylglycerol 
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4.5 Conclusion 
 
The microarray data from this investigation provides some insight into the effect of 
drimane compounds on the Mtb. Many of the genes upregulated in response to treatment with 
drimane compounds were also identified in previous publications. These previous studies 
described the transcriptional response of Mtb to a wide range of stresses. The upregulation of 
genes in our study and also in studies using unrelated compounds indicates that these genes are a 
part of a common cellular response to antimicrobial stresses and overlapping secondary targets. 
Some of the gene identified are also involved in fatty acid and lipid biosynthesis and are 
specifically localized to the cell wall. 
This initial investigation into the gene expression of Mtb treated with drimane 
compounds is not conclusive. It is difficult from this data alone to separate the direct effects of 
drimane compounds on an individual target from the indirect effects. However, the data obtained 
can guide future inquiries. The gene expression of many antibiotics reflect more than just the 
inhibition of a single protein. Future experiments should be conducted to more fully understand 
the indirect and downstream effects of drimane compounds on Mtb. Three future microarray 
studies are proposed below: 
 
• In vitro Microarray Experiments  
The understanding of microbial interactions with the host has been 
enhanced by expression studies using in vitro models to dissect out the complex 
interactions between pathogen and host and then compared to in vivo 
transcriptional data (Wadell and Butcher 2011). The interpretation of this data 
relied upon published studies to help isolate and identify specific signals. 
However it seems that in vitro experiments, that specifically look at the effects of 
drimane compounds on Mtb are needed to facilitate the interpretation of the 
complex data obtained from this broad study. 
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• Analysis of gene expression over a wide range of times 
Understanding the role of temporal changes in gene expression is 
important to the interpretation of complex microarray analysis. mRNA transcript 
expression analysis of early time points after treatment with an antibiotic are not 
likely to include expression changes in the target itself. Differential expression of 
the target gene or of a gene encoding a functionally related protein will eventually 
occur as the organism attempts to compensate for the loss of the target protein 
(Brazas and Hancock, 2005).  
 
• Investigating Gene Expression Over a Range of Concentrations  
 Subsequent microarray experiments should use a range of sub-inhibitory 
concentrations of the drimane compound. It has been suggested that when bacteria 
are treated with antibiotics at low concentrations, expression patterns may 
correlate more with direct target inhibition (Brazas and Hancock, 2005). Also, 
there are biological responses to environmental signals or stresses that are 
characterized by biphasic dose response relationships exhibiting low dose 
stimulation and high dose inhibition. The testing of the transcription at a range of 
concentrations will help isolate the effects on transcription that are in addition to 
their inhibitory properties. 
 
 Even with the proposed additional microarray studies, the cellular target or the 
mechanism of action cannot be elucidated solely by microarray studies. Another approach, 
although arduous and with uncertain results, used to identify the mechanism of action is to 
identify the mutants that are resistant to this compound. This can be done by growing Mtb on 
solid media that contains drimane compounds at a concentration above the MIC and 
subsequently isolating those colonies that are able to survive. This method was successful in the 
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identification of strains of Mtb resistant to diarylquinoline (Koen et al., 2005). These mutants 
were then fully sequenced and shown to have independent point mutations in a subunit of ATP 
synthase. This method is resource intense because it requires the ability to fully sequence 
bacterial genomes. While this method was not initially successful when tried in our lab using 
twice the MIC, it should be investigated again.  
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Appendix B 
 
Selected NMR Spectra of Isolated Drimane Sesquiterpenes 
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!! !!! Appendix B1. 1H NMR Spectra of HPLC fraction 7. This compound was identified to be drimane 
sesquiterpenesmuzigadial. 
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!!!
 Appendix B2. gCOSY NMR Spectra of HPLC fraction 7. This compound was identified to be drimane sesquiterpene muzigadial. 
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!!
Appendix B3. 1H NMR Spectra of HPLC fraction 14. This compound was identified to be drimane sesquiterpene 
warburganal. 
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!!
Appendix B4. gCOSY Spectra of HPLC fraction 14. The most abundant compound was identified to be drimane 
sesquiterpene warburganal. 
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APPENDIX C 
!
!
Genes Upregulated More Than 1.5 Times  
In Microarray Analysis
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Gene Name 4h 24h Function 
  Normalized t-test  Normalized t-test    
  P-value  P-value  
rv0026 2.14 0.04 2.79 0.19 HP 
rv0027 1.65 0.04 1.77 0.01 Unknown function conserved hypothetical protein gene product 
rv0048c 1.56 0.04 1.59 0.01 unknown possible membrane protein 
rv0067c 3.17 0.01 2.41 0.05 possibly involved in transcritional regulatory mechanism 
rv0068 3.48 0 4.13 0.02 Function unknown; probably involved in cellular metabolism 
sdaa 
(rv0069c) 2.65 0.13 1.86 0 sdaA L-serine dehydratase SdaA 
rv0132c 1.76 0.08 1.58 0.08 fgd2 f420-dependent glucose-6-phosphate dehydrogenase 
rv0136 2.08 0.12 1.93 0.04 cytochrome P450 138 
rv0137c 1.52 0.26 1.69 0.24 msrA, methionine sulfoxide reductase A 
rv0146 1.53 0.01 2.08 0.23 Function unknown. Possible methyltransferase. 
bgls (rv0186) 1.51 0.01 1.52 0.08 beta-glucosidase 
rv0195 1.66 0.26 3.32 0.01 Part of two component system, probably LuxR 
rv0213c 7.51 0 2.23 0 Methyltransferase 
rv0219 2 0.01 3.11 0.02 Unknown 
lpqi (rv0237) 1.77 0.24 2.47 0.23 Lipoprotein 
fada2 
(rv0243) 1.97 0.01 1.53 0.08 acetyl-CoA acetyltransferase 
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Gene Name 4h 24h Function 
  Normalized t-test  Normalized t-test    
  P-value  P-value  
fade5 
(rv0244c) 1.51 0.02 2.26 0.04 acyl-CoA dehydrogenase  
rv0250c 1.97 0.09 1.84 0 Function unknown 
hsp 
(rv0251c) 1.76 0.05 2.4 0.05 heat shock protein  
cobq 
(rv0255c) 1.99 0.05 2.99 
no 
replicates cobyric acid synthase 
naru (rv0267) 2.09 0.02 2.68 0.02 Integral membrane nitrite extrusion protein 
rv0327c 1.78 0.03 1.77 0.16 cytochrome P450  
rv0331 2.05 0.12 1.83 0.22 Function unknown 
clpb 
(rv0384c) 1.83 0.03 1.63 0.07 endopeptidase ATP binding protein 
rv0416 1.93 0.01 2.53 0 sulfur carrier protein 
rv0424c 1.68 0.07 1.5 0.13 Unknown function conserved hypothetical protein gene product 
rv0452 1.67 0.01 2.16 0.03 Possible involved in a transcriptional mechanism 
rv0465c 1.59 0.23 2.54 0.08 Possible involved in a transcriptional mechanism 
acea (rv0467) 1.57 0.02 2.35 0.02 icl isocitrate lyase 
rv0532 1.82 0.08 1.68 0.07 PE-PGRS family protein 
htpx (rv0563) 1.91 0.09 2.38 0 heat shock protein 
rv0585c 1.94 0.01 2.7 0.04 Probable conserved integral membrane protein 
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Gene Name 4h 24h Function 
  Normalized t-test  Normalized t-test    
  P-value  P-value  
rv0585c 1.94 0.01 2.7 0.04 Probable conserved integral membrane protein 
mmpl5 
(rv067c) 2.95 0.06 3.16 0.01 transmembrane transport protein MmpL5 
mmps5 
(rv0677c) 3.97 0.01 3.86 0.02 Conserved membrane protein 
rv0678 5.24 0.02 3.67 0 Unknown function conserved hypothetical protein gene product 
rv0690c 1.6 0 1.9 0.01 Unknown function conserved hypothetical protein gene product 
rplc (rv0701) 1.83 0.01 1.59 0.04 50S ribosomal protein 
atsa (rv0711) 1.8 0.03 2.68 0 arylsulfatase AtsA 
xylb (rv0729) 1.78 0.04 3.12 0.06 xylB D-xylulose kinase XylB 
rv0754  1.77 0.32 2.17 0 PE-PGRS family protein 
rv0802c 1.51 0.01 1.64 0.02 Aceylation substrate unknown 
rv0810c 1.7 0.09 2.03 0.03 Unknown function conserved hypothetical protein gene product 
lpqr (rv0838) 1.79 0.02 2.03 0.06 lpqR lipoprotein 
cysm3 
(rv0848) 1.52 0.01 2.33 0 cysteine synthase A 
rv0849 1.62 0 2.53 0.04 Thought to be involved in the transport of an unknown substrate across the membrane 
rv0850 1.6 0.22 2.84 0.07 required for the transposition of an insertion element 
rv0981 2.39 0.04 1.73 0.04 mprA two component response transcriptional regulatory protein MprA 
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Gene Name 4h 24h Function 
  Normalized t-test  Normalized t-test    
  P-value  P-value  
rv0997 2.2 0.02 2.14 0.3 Unknown function conserved hypothetical protein gene product 
pabb 
(rv1005c) 1.88 0.01 2.08 0.05 aminodeoxychorismate synthase component I 
rv1057 2.77 0.02 2.91 0.03 Function unknown 
rv1073 1.86 0.04 2.35 0 Unknown function conserved hypothetical protein gene product 
lytb' (rv1110) 1.63 0.02 1.61 0.07 LYTB-like protein  
rv1174c 2.41 0 1.68 0.01 T-cell antigen 
pks3 
(rv1180) 1.86 0.08 3.84 0.05 polyketide beta-ketoacyl synthase PKS3 
papa3 
(rv1182) 2.42 0.34 3.01 0.3 polyketide synthase associated protein PapA3 
rv1184c 1.89 0.11 3.41 0.07 hypothetical protein 
fadd21 
(rv1185c) 1.78 0.02 2.51 0.07 acyl-CoA synthetase 
rv1200 1.61 0.07 1.89 0.02 Thought to be involved in a transport system across the membrane 
rv1216c 3.08 0 1.79 0.02 Probable integral membrane protein 
rv1217c 3.28 0.01 1.62 0 Thought to be involved in a transport system across the membrane 
rv1218c 3.89 0.01 2.52 0 Thought to be involved in a transport system across the membrane 
rv1219c 3.02 0.05 2.29 0.04 Involved in transcriptional mechanism 
rv1347c 1.5 0 2.76 0.06 Acylation substrate unknonwn 
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!!!! !Gene Name 4h 24h Function   Normalized t-test  Normalized t-test    
  P-value  P-value  
rv1353c 2.19 0.03 2.43 0.23 Probable trascritional regulatory protein 
rv1390 1.61 0.13 2.45 0.11 DNA-directed RNA polymerase subunit  
pria (rv1402) 1.59 0.28 1.55 0.11 priA primosome assembly protein  
rv1403c 1.98 0.12 2.56 0.02 Putative methyl transferase 
trxa (rv1470) 1.62 0.02 1.53 0.02 thioredoxin TRXA 
rv1791 1.54 0.02 1.56 0.2 PE family protein 
rv1792 3.07 0.05 2.19 0.16 Pseudo 
rv1803c 1.7 0.03 2.42 0.03 PE-PGRS family protein 
rv1806 2.04 0.03 4.45 0.02 PE family protein 
rv1807 1.56 0.02 2.43 0.02 PPE family protein 
rv1808 1.7 0.03 3.02 0.04 PPE family protein 
rv1809 1.75 0.13 3.2 0.06 PPE family protein 
rv1810 1.52 0.02 2.18 0.02 Unknown function conserved hypothetical protein gene product 
rv1945 1.82 0.04 1.58 0.02 Unknown function conserved hypothetical protein gene product 
rv2037c 2.01 0.2 2.62 0.24 Unknown, possible conserved trans-membrane protein 
rv2050 1.9 0.13 2.14 0.12 Unknown function conserved hypothetical protein gene product 
rv1353c 2.19 0.03 2.43 0.23 Probable trascritional regulatory protein 
rv1390 1.61 0.13 2.45 0.11 DNA-directed RNA polymerase subunit  
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!!!!! !Gene Name 4h 24h Function   Normalized t-test  Normalized t-test      P-value  P-value  
pria (rv1402) 1.59 0.28 1.55 0.11 priA primosome assembly protein  
rv1403c 1.98 0.12 2.56 0.02 Putative methyl transferase 
trxa (rv1470) 1.62 0.02 1.53 0.02 thioredoxin TRXA 
rv1791 1.54 0.02 1.56 0.2 PE family protein 
rv1792 3.07 0.05 2.19 0.16 Pseudo 
rv1803c 1.7 0.03 2.42 0.03 PE-PGRS family protein 
rv1806 2.04 0.03 4.45 0.02 PE family protein 
rv1807 1.56 0.02 2.43 0.02 PPE family protein 
rv1808 1.7 0.03 3.02 0.04 PPE family protein 
rv1809 1.75 0.13 3.2 0.06 PPE family protein 
rv1810 1.52 0.02 2.18 0.02 Unknown function conserved hypothetical protein gene product 
rv1945 1.82 0.04 1.58 0.02 Unknown function conserved hypothetical protein gene product 
rv2037c 2.01 0.2 2.62 0.24 Unknown, possible conserved trans-membrane protein 
rv2050 1.9 0.13 2.14 0.12 Unknown function conserved hypothetical protein gene product 
rv2094c 1.6 0.01 1.95 0.01 arginine translocase protein A 
rv2100 1.92 0.02 1.64 0.05 Unknown function conserved hypothetical protein gene product 
rv2182c 1.59 0.01 1.72 0.01 transfer of fatty acyl groups 
! 140!
!!! !Gene Name 4h 24h Function 
  Normalized t-test  Normalized t-test    
  P-value  P-value  
rv2333c 1.86 0.03 2.2 0.06 Thought to be involved in a transport system across the membrane  
rv2347c 3.67 0.02 4.51 0.07  ESAT-6 like protein  
mbtd 
(rv2381c) 1.7 0.07 2.4 0.03 polyketide synthetase 
trpe2 
(rv2386c) 1.57 0.07 3.27 0.04 component I of anthranilate synthase 
ahpc 
(rv1792) 1.55 0.15 1.93 0.05 alkyl hydroperoxide reductase subunit C 
clpP2 
(rv2460c) 1.85 0.02 2.05 0.02 ATP-dependent Clp protease proteolytic subunit 
rv2541 2.51 0.02 1.85 0.01 Unknown 
rv2694c 3.01 0.34 2.6 0.03 Unknown function conserved hypothetical protein gene product 
rv2699c 1.67 0.02 2.73 0.09 Unknown function conserved hypothetical protein gene product 
sigb (rv2710) 7.33 0.12 2.59 0.02 RNA polymerase sigma factor SigB 
35kd_ag 
(rv2744c) 1.81 0.25 1.67 0.13 hypothetical protein 
rv2745c 1.85 0.01 1.66 0.1 Possibly involved in transcriptional mechanism 
rv2802c 1.73 0.01 1.86 0.12 Unknown 
rv2824c 2.65 0.16 2.26 0.03 HP 
gcpe 
(rv2868c) 1.5 0.08 1.56 0.08 biosynthesis of secondary metabolites 
rv3054c 1.59 0.03 3.01 0.11 hypothetical protein 
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  Normalized t-test  Normalized t-test    
  P-value  P-value  
rv3160c 4.62 0 3.23 0.04 Possibly involved in transcriptional mechanism. 
rv3161c 2.51 0.01 2.37 0.09 Function unknown; probably involved in cellular metabolism 
lipv (rv3203) 1.67 0.01 1.74 0.01 lipV lipase LipV 
rv3402c 2.04 0.05 4.68 0.04 Unknown function conserved hypothetical protein gene product 
rv3406 2.24 0.07 2.26 0.02 Function unknown; probably involved in cellular metabolism 
whib3 
(rv3416) 1.67 0.03 2.1 0.04 transcriptional regulatory protein WHIB-like 
rv3430c 1.67 0.51 1.56 no replicates Possible transposase 
rv3520c 1.51 0.16 1.67 0.02 Function unknown probably involved in cellular metabolism 
rv3539 1.56 0.04 1.68 0.02 PPE family protein 
rv3588c 1.52 0.01 1.55 0.34   
fole 
(rv3609c) 2.09 0.05 1.78 0.02 GTP cyclohydrolase I 
rv3615c 1.68 no replicates 2.82 0.14 
Unknown function conserved hypothetical protein 
gene product 
rv3765c 1.69 0.05 2.21 0.02 two component transcriptional regulatory protein 
rv3766 1.66 0.03 1.82 0.03 Unknown function conserved hypothetical protein gene product 
rv3767c 1.53 0.1 3.12 0 Function unknown. Possible methyltransferase. 
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!!
Gene Name 4h 24h Function 
  Normalized t-test  Normalized t-test    
  P-value  P-value  
epib (rv3784) 1.51 0.01 1.82 0.02 Possibly involved in biosynthesis pathway of lipopolysaccharide biosynthesis 
rv3802c 1.68 0 1.77 0.02 Unknown function conserved hypothetical protein gene product 
papa1 
(rv3824c) 2.12 0 2.86 0.1 polyketide synthase associated protein 
pks2 
(rv3825c) 2.88 0.01 3.88 0.09 polyketide synthase  
rv3830c 1.54 0.05 3.63 0.01 transcriptional regulatory protein 
rv3862c 1.86 0.03 2.27 0.02 transcriptional regulatory protein WHIB-like WHIB6 
rv3880c 4.19 0.03 1.82 0.02 Unknown function conserved hypothetical protein gene product 
MT2619 1.56 0.14 1.9 0.02 Lipoprotein 
MT1746.1 1.68 no replicates 2.54 0.08 
Unknown function conserved hypothetical protein 
gene product 
MT3297 1.61 0.25 1.52 0.13 hypothetical protein 
MT2467 1.98 0.19 2.96 0 PE-PGRS family protein 
MT1025.2 1.75 0.02 1.83 0 hypothetical protein 
